<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention and management of side effects in patients receiving opioids for chronic pain</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention and management of side effects in patients receiving opioids for chronic pain</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention and management of side effects in patients receiving opioids for chronic pain</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell K Portenoy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Zankhana Mehta, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ebtesam Ahmed, PharmD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet Abrahm, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Opioids represent a mainstay for treatment of severe chronic pain in patients with active cancer or other serious chronic illnesses. Although the side effect liability of these drugs is significant and they are inherently associated with the serious problems of drug abuse and addiction, experience in the management of cancer pain indicates that they can potentially be used safely and effectively for all types of pain (ie, somatic, visceral, neuropathic). (See  <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia"</a> and  <a class="medical medical_review" href="/z/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids"</a>.)</p><p>The term "chronic non-cancer pain" is ill defined but generally understood to apply to common types of musculoskeletal pain syndromes, such as arthritis and low back pain, and to headache. The long-term use of opioid drugs for these conditions is more controversial than use for cancer-related pain. For patients with chronic non-cancer pain, the decision to begin opioid therapy must be weighed carefully. (See  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain"</a> and  <a class="medical medical_review" href="/z/d/html/126633.html" rel="external">"Pharmacologic management of chronic non-cancer pain in adults", section on 'Opioids'</a>.)</p><p>The public health consequences of opioid abuse drive the imperative that all clinicians assume responsibility for risk management when these drugs are prescribed for legitimate medical purposes. This applies to opioid use of any type in any population. (See  <a class="medical medical_review" href="/z/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids", section on 'Risk assessment and management for patients receiving opioids'</a> and  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a> and  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain", section on 'Evaluation of risk prior to initiating therapy'</a>.)</p><p>Opioid therapy is associated with numerous side effects, the most common of which are gastrointestinal or neurologic. There is marked interindividual variability in the sensitivity to adverse effects from opioids, which may be due to genetic differences, age, comorbidity, or interactions with other drugs. The assessment and management of side effects is a best practice during opioid therapy. In many cases, however, a favorable balance between analgesia and side effects cannot be attained, a situation that may be termed "poor responsiveness." When a patient undergoing dose titration is determined be poorly responsive to a specific opioid, there are several approaches to consider: improving the symptomatic management of the dose-limiting side effect, changing to an alternative opioid (opioid rotation), or adding another therapy (a nonopioid analgesic, an adjuvant analgesic, or a nonpharmacologic treatment) that may improve analgesia even as the opioid dose is lowered.</p><p>This topic review will cover the prevention and management of specific adverse events in patients receiving chronic opioid therapy. Management of side effects in patients receiving opioid therapy for acute pain in the postoperative or acute critical illness settings is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OPIOID BOWEL DYSFUNCTION</span><span class="headingEndMark"> — </span>It has long been recognized that opioids affect gastrointestinal motility. The usual effects include increased segmental motility and decreased peristalsis. The outcome usually is manifest as constipation. Motility disturbances and other opioid-related effects also may lead to nausea, bloating, early satiety, or pain. Occasionally, patients develop ileus or a syndrome characterized by a relatively high level of abdominal pain, a condition that has been termed "narcotic bowel syndrome" [<a href="#rid1">1</a>]. Theoretically, the pain in this condition may be related to an interaction between increased nonpropulsive motility and visceral hyperalgesia, such as what occurs in functional gastrointestinal disorders. If the phenomenon of visceral hyperalgesia is occurring, it could, in turn, be related to the phenomenon of opioid-induced hyperalgesia. However, there is no direct evidence to support the latter pathophysiology. (See <a class="local">'Opioid-induced hyperalgesia'</a> below.)</p><p class="headingAnchor" id="H3155008693"><span class="h2">Constipation</span><span class="headingEndMark"> — </span>In opioid-treated cancer patients, the prevalence of constipation can be as high as 60 to 90 percent, and for clinical purposes, it is assumed that the opioid plays an important role irrespective of other contributory factors [<a href="#rid2">2</a>]. Constipation can significantly impact quality of life, as well as opioid use patterns, resource utilization, and costs [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H3"><span class="h3">Contributory factors</span><span class="headingEndMark"> — </span>Multiple factors contribute to the development of opioid-induced constipation (OIC) in patients receiving systemic opioids:</p><p class="bulletIndent1"><span class="glyph">●</span>Opioids bind to specific receptors in the gastrointestinal tract and central nervous system to reduce peristalsis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Longer gastrointestinal transit time causes excessive water and electrolyte reabsorption from feces, and decreased biliary and pancreatic secretion further dehydrates stool.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent use of other constipating drugs (eg, tricyclic antidepressants), dehydration, advancing age, immobility, metabolic abnormalities (eg, hypercalcemia), chemotherapy (particularly treatment with the vinca alkaloids), and tumor-related bowel obstruction may also contribute. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Constipation'</a> and  <a class="medical medical_review" href="/z/d/html/85393.html" rel="external">"Palliative care of bowel obstruction in cancer patients"</a>.)</p><p></p><p>Not all opioid formulations are equally constipating. Although the results of randomized trials are conflicting [<a href="#rid5">5-8</a>], two systematic reviews of patients receiving opioids for cancer and non-cancer pain concluded that there is less constipation with transdermal <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> than with oral sustained-release <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid9">9,10</a>]. There have been no direct comparisons of the constipating effects of these drugs, and in the absence of anecdotal reports of differential effects on the gut, the explanation for these observations has focused on the route of administration. The non-oral route presumably impacts opioid receptors less than the oral route and, for this reason, may be less constipating. (See  <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia", section on 'Fentanyl'</a>.)</p><p>In addition, a combined preparation of long-acting <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> in a fixed 2:1 ratio is available in some countries and is associated with less constipation, and no compromise in analgesic efficacy (in the approved dose range) or safety compared with an equivalent dose of oxycodone alone [<a href="#rid11">11</a>]. (See <a class="local">'Other orally administered opioid antagonists'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of OIC should be based upon clinical history, appropriate physical examination (including a rectal examination, unless not indicated), and limited diagnostic tests. Diagnostic criteria for OIC are available (the ROME-IV criteria) [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>New or worsening symptoms of constipation when initiating, changing, or increasing opioid therapy, which must include two or more of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Straining during more than one-fourth of defecations</p><p class="bulletIndent2"><span class="glyph">•</span>Lumpy or hard stools in more than one-fourth of defecations</p><p class="bulletIndent2"><span class="glyph">•</span>Sensation of incomplete evacuation in more than one-fourth of defecations</p><p class="bulletIndent2"><span class="glyph">•</span>Sensation of anorectal obstruction/blockage in more than one-fourth of defecations</p><p class="bulletIndent2"><span class="glyph">•</span>Manual maneuvers to facilitate more than one-fourth of defecations (eg, digital evacuation, support of the pelvic floor)</p><p class="bulletIndent2"><span class="glyph">•</span>Fewer than three spontaneous bowel movements per week</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, severe OIC can produce obstipation with postobstructive diarrhea</p><p></p><p>If constipation develops or worsens in parallel with changes in the opioid regimen, no further evaluation is needed. However, when there is no clear precipitant, an assessment for alternative or contributory causes should be undertaken. The physical examination should be focused to determine if an organic problem exists to account for symptoms [<a href="#rid12">12</a>]. A careful anorectal examination can identify structural issues and fecal impaction.</p><p>Few data are available regarding the clinical utility of tests in suspected OIC. If clinically indicated, simple laboratory tests (eg, complete blood count, serum calcium, thyroid-stimulating hormone) are reasonable, as hypercalcemia and hypothyroidism may contribute to constipation. An abdominal plain radiograph can identify fecal impaction and the level of stool burden. Occasionally, colonoscopy is indicated to assess a possible coexisting intraluminal lesion. Potentially remediable contributors to constipation should be managed appropriately.</p><p class="headingAnchor" id="H3695326310"><span class="h3">Prevention</span><span class="headingEndMark"> — </span>Prevention is the preferred strategy. All patients with predisposing factors (eg, advanced age, immobility, poor diet, intra-abdominal pathology, neuropathy, hypercalcemia, concurrent use of other constipating drugs) should be considered for prophylactic laxative therapy when opioid treatment is initiated. Conventionally, this is accomplished using either a contact cathartic (eg, <a class="drug drug_general" data-topicid="10260" href="/z/d/drug information/10260.html" rel="external">senna</a>, two tablets at bedtime to start), an osmotic laxative (eg, polyethylene glycol, <a class="drug drug_general" data-topicid="9543" href="/z/d/drug information/9543.html" rel="external">lactulose</a>, or <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a>), or both. There are many options. Some patients may have previously tried a contact cathartic and do not favor this approach because of abdominal cramping. They can be treated with a daily dose of an osmotic laxative (eg, polyethylene glycol [PEG] 17 g [one heaping tablespoon] or lactulose [30 mL]). Yet, other patients tolerate the contact cathartic but benefit from as-needed administration of the osmotic laxative (eg, PEG 17 g [one heaping tablespoon] or lactulose [30 mL] as needed). In general, we would avoid use of lactulose in lactose-intolerant patients. Finally, some patients are troubled by hard and dry stools, and for this problem, the surfactant <a class="drug drug_general" data-topicid="9382" href="/z/d/drug information/9382.html" rel="external">docusate</a> can be added on a daily basis to the contact cathartic. All patients should be encouraged to increase fluid intake and mobility; the intake of soluble dietary fiber also should be increased unless the patient is debilitated, has limited oral fluid intake, or bowel obstruction is suspected. In addition, comfort and privacy for defecation must be ensured  (<a class="graphic graphic_table graphicRef60646" href="/z/d/graphic/60646.html" rel="external">table 1</a>). Use of a squatting posture can improve defecation as it is thought to straighten the anorectal angle to reduce straining [<a href="#rid13">13</a>]. Devices to promote a squatting or semi-squatting position are commercially available [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1092358653"><span class="h3">Initial management</span><span class="headingEndMark"> — </span>The following reflects our approach to initial management:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are at increased risk of OIC or develop OIC, we suggest starting with conventional laxatives as first-line agents. The choice of agent and the dosing are empiric. Although one small randomized trial suggested that sennosides were as effective as, but less expensive than, <a class="drug drug_general" data-topicid="9543" href="/z/d/drug information/9543.html" rel="external">lactulose</a> [<a href="#rid15">15</a>]; there are no adequately powered randomized trials comparing sennosides, lactulose, or PEG [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">If a patient is tolerating conventional laxative therapy, but it has been insufficiently effective, dose escalation should be considered. The contact cathartic dose can be doubled or tripled unless the patient develops abdominal cramping or diarrhea. The dose of an osmotic laxative can be increased (given once or twice daily) until diarrhea occurs, then the dose is lowered. Alternatively, a patient whose preventative regimen is ineffective can be switched to a different conventional laxative strategy (eg, from a contact cathartic to an osmotic cathartic, or vice versa)  (<a class="graphic graphic_table graphicRef60646" href="/z/d/graphic/60646.html" rel="external">table 1</a>). We would avoid use of <a class="drug drug_general" data-topicid="9543" href="/z/d/drug information/9543.html" rel="external">lactulose</a> in lactose-intolerant patients, and we restrict use of a stool softener, such as <a class="drug drug_general" data-topicid="9382" href="/z/d/drug information/9382.html" rel="external">docusate</a>, to patients who describe hard, dry stools.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have passed no stool in several days and who have no evidence of bowel obstruction or ileus may be impacted. It is often possible to clear the rectal vault and lower sigmoid colon with a <a class="drug drug_general" data-topicid="10213" href="/z/d/drug information/10213.html" rel="external">mineral oil</a> enema followed by an irritant enema, but manual disimpaction may be required. Once an impaction has been ruled out or cleared, laxative therapy may be started.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients also are able to improve bowel function through dietary modifications (increased consumption of fluids and soluble dietary fiber) and increased physical activity. Fiber should not be increased if the patient is debilitated, fluid intake is limited, or bowel obstruction is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regular ingestion of probiotics can improve chronic constipation; given the safety of these therapies, a trial in patients with OIC is reasonable. (See <a class="local">'Other therapies'</a> below.)</p><p></p><p>The use of conventional laxative therapy is recommended based on extensive experience; there continues to be limited high-quality evidence of efficacy for OIC [<a href="#rid16">16-20</a>]. There is evidence of benefit in chronic idiopathic constipation; however, in a systematic review and meta-analysis from 2011 examining the efficacy of laxatives in chronic idiopathic constipation [<a href="#rid21">21</a>], the authors identified seven randomized controlled trials evaluating 1411 patients (laxatives, n = 876; placebo, n = 535) treated with stimulant or osmotic laxatives; laxatives were found to be superior to placebo for spontaneous bowel movement response (pooled risk ratio [RR] 2.24, 95% CI 1.93-2.61) and change in bowel movement frequency (mean difference between the laxative and placebo groups was an increase of 2.55 [1.53 more to 3.57 more]). Laxatives were also associated with a reduction in straining (RR 1.52, 95% CI 1.18-1.96), an improvement in stool consistency, and a reduction in passage of hard stools (RR 1.55, 95% CI 1.33-1.82). (See  <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">"Management of chronic constipation in adults", section on 'Other laxatives'</a> and  <a class="medical medical_review" href="/z/d/html/2665.html" rel="external">"Bowel preparation before colonoscopy in adults"</a>.)</p><p>There are numerous options for conventional laxative therapy  (<a class="graphic graphic_table graphicRef73845" href="/z/d/graphic/73845.html" rel="external">table 2</a>) and no data to suggest that any one approach is superior to any other. In a Cochrane systematic review of management of OIC in a population with advanced illness, four randomized trials comparing different kinds of laxatives showed no significant differences among them [<a href="#rid22">22</a>]. The specific approach selected should be consistent with patient preference  (<a class="graphic graphic_table graphicRef60646" href="/z/d/graphic/60646.html" rel="external">table 1</a>). For patients who are lactose intolerant, <a class="drug drug_general" data-topicid="9543" href="/z/d/drug information/9543.html" rel="external">lactulose</a> may cause excessive gas and abdominal pain, cramping, and bloating; it should be avoided in these patients [<a href="#rid23">23</a>].</p><p>Previously, it was common to use a stool softener in conjunction with a laxative, but studies now suggest that it need not be included:</p><p class="bulletIndent1"><span class="glyph">●</span>There is little evidence to support the use of surfactant agents in chronic constipation. Stool softeners, such as <a class="drug drug_general" data-topicid="9382" href="/z/d/drug information/9382.html" rel="external">docusate</a> sodium, are intended to lower the surface tension of stool, thereby allowing water to more easily enter the stool. Although these agents have few side effects, they are less effective than other laxatives [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">"Management of chronic constipation in adults", section on 'Surfactants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no significant benefit of <a class="drug drug_general" data-topicid="9382" href="/z/d/drug information/9382.html" rel="external">docusate</a> plus sennosides compared with placebo plus sennosides in managing constipation in a randomized trial conducted in 74 hospice patients; over 95 percent of the enrolled patients received opioids during each of the 10 days of the trial [<a href="#rid25">25</a>].</p><p></p><p>Given these limited observations, it would be reasonable to individualize the use of a stool softener, such as <a class="drug drug_general" data-topicid="9382" href="/z/d/drug information/9382.html" rel="external">docusate</a>, and use it when patients describe hard, dry stools. In practice, clinicians often simply coadminister docusate and a contact cathartic, such as <a class="drug drug_general" data-topicid="10260" href="/z/d/drug information/10260.html" rel="external">senna</a>, as a first-line approach to constipation, without regard for the presence of specific indications for the surfactant.</p><p class="headingAnchor" id="H5"><span class="h3">Management of refractory opioid-induced constipation</span><span class="headingEndMark"> — </span>When conventional approaches are insufficiently effective, strategies that are used in refractory situations should be considered. For refractory cases of OIC, there are numerous approaches  (<a class="graphic graphic_table graphicRef73845" href="/z/d/graphic/73845.html" rel="external">table 2</a>), including opioid receptor antagonist therapy and <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">lubiprostone</a>, which are specifically approved for this indication. Although many of these drugs, including lubiprostone, have not been tested directly in cancer patients, and their US Food and Drug Administration (FDA) approvals are for OIC in patients with noncancer pain, they are used in refractory OIC in patients with cancer.</p><p>In general, we prefer a peripherally acting mu-opioid receptor antagonist (PAMORA) for most patients. The choice of agent is empiric, as there are no high quality trials directly comparing any of the available agents [<a href="#rid26">26</a>]. For most patients, we suggest <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a>. If an oral agent is preferred, options include <a class="drug drug_general" data-topicid="97147" href="/z/d/drug information/97147.html" rel="external">naloxegol</a>, oral methylnaltrexone, or where available, <a class="drug drug_general" data-topicid="112482" href="/z/d/drug information/112482.html" rel="external">naldemedine</a>.</p><p>Consensus-based recommendations for the use of prescription drugs for OIC are available from the American Gastroenterological Association (AGA) [<a href="#rid27">27</a>]. These guidelines, which recommend use of the Bowel Function Index (BFI) to evaluate OIC  (<a class="graphic graphic_table graphicRef106673" href="/z/d/graphic/106673.html" rel="external">table 3</a>) [<a href="#rid28">28</a>], suggest that prescription therapies be considered for a score of ≥30 points in patients with previous or current use of first-line interventions (laxatives, stool softeners, bulk agents). However, in the clinical setting, the decision to proceed to a trial of a prescription drug for OIC is more typically based on a broader assessment, which may include factors as varied as the patient’s level of constipation-associated distress, psychologic reaction to the possibility of another over-the-counter strategy, and extent of insurance coverage for the cost of prescription medications. Given the large number of over-the-counter treatments, which may be tried in combination and at varied doses, the decision to label the patient’s symptoms as "refractory" and proceed to a prescription-based approach is ultimately determined through discussion with the patient about the burdens, risks, and costs associated with the next trial.</p><p class="headingAnchor" id="H372619437"><span class="h4">Opioid antagonists</span><span class="headingEndMark"> — </span>We suggest peripherally acting mu-opioid receptor antagonists (PAMORAs) for refractory OIC in the absence of bowel obstruction. These agents should be avoided in the presence of bowel obstruction.</p><p>The benefit of PAMORAs as a group for treatment of refractory OIC in patients with cancer or another advanced illness has been addressed in the following meta-analyses:</p><p class="bulletIndent1"><span class="glyph">●</span>A year 2022 Cochrane review summarized results from ten trials, totaling 1343 adults with cancer irrespective of stage or at a palliative care stage of any disease [<a href="#rid29">29</a>]. There were two trials of oral <a class="drug drug_general" data-topicid="112482" href="/z/d/drug information/112482.html" rel="external">naldemedine</a>, three of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> in combination with <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>, one of naloxone alone, and four of subcutaneous <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a>. The following conclusions were reached:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All trials were vulnerable to bias, mostly because of a high risk of detection bias due to nonblinded outcome assessment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There was moderate-certainty evidence to suggest that, taken orally, <a class="drug drug_general" data-topicid="112482" href="/z/d/drug information/112482.html" rel="external">naldemedine</a> improves bowel function over two weeks in people with cancer and OIC (two trials, 418 participants, RR 2.00, 95% CI 1.59-2.52), and there was very-low-certainty evidence that naldemedine had no effect on opioid withdrawal (one trial, 112 participants). However, naldemedine increased the risk of adverse events (two studies, 418 patients, RR 1.49, 95% CI 1.19-1.87, moderate-quality evidence), the most common of which was diarrhea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The data were insufficient to judge the benefits and risks of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> alone compared with placebo (one crossover trial, 17 patients). There was low-certainty evidence that <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>/naloxone had no effect on analgesia. No trial evaluated laxation response of combined therapy over the first two weeks of administration. There was very-low-certainty evidence that oxycodone/naloxone did not increase the risk of serious adverse events, and there was low-certainty evidence that it did not increase the risk of any adverse events.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">Methylnaltrexone</a> improved bowel function, with more spontaneous laxations within 24 hours (two studies, 287 patients, RR 2.97, 95% CI 2.13-4.13, low-certainty evidence), and over two weeks (two studies, 305 patients, RR 8.15, 95% CI 4.76-13.95], moderate-certainty evidence) in people receiving palliative care. Methylnaltrexone also increased the proportion of patients reporting improved bowel status at the end of the trial (2 studies, 287 patients, RR 2.32, 95% CI 1.64-3.27, low-certainty evidence). There was low-certainty evidence that the rate of opioid withdrawal was not affected by methylnaltrexone, and low-certainty evidence that it increased adverse events (three studies, 518 patients, RR 1.17, 95% CI 1.05-1.30). There was little to no difference in risk of spontaneous laxations or in patient assessment of improved bowel status, or in symptoms of opioid withdrawal with lower versus higher doses of methylnaltrexone (1 versus ≥5 mg subcutaneously).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A separate meta-analysis evaluated 23 placebo-controlled trials of PAMORAs, and concluded that <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a>, <a class="drug drug_general" data-topicid="112482" href="/z/d/drug information/112482.html" rel="external">naldemedine</a>, <a class="drug drug_general" data-topicid="97147" href="/z/d/drug information/97147.html" rel="external">naloxegol</a>, and <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> were all superior to placebo, with a RR of failure to respond to therapy of 0.63 (95% CI 0.56-0.71) for naloxone (five trials, 838 participants, moderate-certainty evidence), 0.65 (95% CI 0.52-0.82) for naldemedine (four trials, 1525 participants, moderate-certainty evidence), 0.77 (95% CI 0.61-0.97) for naloxegol (three trials, 1522 participants, moderate-quality evidence), 0.68 (95% CI 0.58-0.80) for <a class="drug drug_general" data-topicid="9057" href="/z/d/drug information/9057.html" rel="external">alvimopan</a> (four trials, 1579 participants, moderate-certainty evidence), and 0.62 (95% CI 0.50-0.76) for methylnaltrexone (six trials, 1622 participants, high-quality evidence).</p><p></p><p>The following sections will review the data for individual agents.</p><p class="headingAnchor" id="H4580064"><span class="h5">Methylnaltrexone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">Methylnaltrexone</a> is a PAMORA, and like other drugs in this class it has a restricted ability to cross the blood brain barrier. It does not induce symptoms of opioid withdrawal. In the United States, subcutaneous methylnaltrexone is approved for OIC in patients with chronic non-cancer pain and for patients with any advanced illness receiving palliative care who have had an inadequate response to traditional laxatives. Oral methylnaltrexone (450 mg once daily) is approved for OIC in patients with chronic non-cancer pain; it can be used off-label for patients with cancer and OIC.</p><p>The efficacy of subcutaneous <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a> for the treatment of OIC has been shown in multiple randomized trials and confirmed in several meta-analyses [<a href="#rid22">22,30-32</a>]. In a network analysis of 21 randomized controlled trials evaluating drugs used in OIC, subcutaneous methylnaltrexone was significantly better at reversing OIC than <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">lubiprostone</a>, <a class="drug drug_general" data-topicid="97147" href="/z/d/drug information/97147.html" rel="external">naloxegol</a>, oral methylnaltrexone, and <a class="drug drug_general" data-topicid="83328" href="/z/d/drug information/83328.html" rel="external">prucalopride</a> (a highly selective 5-hydroxytryptamine type 4 [5HT4] receptor agonist that acts as a prokinetic in the gut) [<a href="#rid31">31,33</a>].</p><p>When used chronically, <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a> may be given subcutaneously once every other day or every third day; the frequency of administration can be increased, if needed, but should not exceed once daily. The approved dose of the injectable formulation is 8 mg for patients weighing 38 to 61 kg and 12 mg for those weighing 62 to 114 kg; for those outside these ranges, the recommended dose is 0.15 mg/kg. Long-term administration of methylnaltrexone is effective and safe [<a href="#rid34">34,35</a>].</p><p>Higher doses may provide additional benefit, although the data are limited. In the trial described above, a subgroup of 41 patients received dose escalation during the second week of therapy because of limited effectiveness (20 in the <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a> group, 21 in the placebo group at an equivalent volume) [<a href="#rid36">36</a>]. The fraction of patients who had a bowel movement within four hours of increasing the methylnaltrexone dose to 0.3 mg/kg was 24 percent (compared with 15 percent within four hours of the prior dose of 0.15 mg/kg). The corresponding rates in the placebo group were 8 percent before and 7 percent after dose escalation. The pattern of adverse events in patients who had dose escalation did not differ in either group.</p><p>Although less data are available, the available evidence also suggests that oral <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a> is effective and well tolerated for treatment of OIC without adversely impacting analgesia, at least in patients with chronic non-cancer pain [<a href="#rid37">37-39</a>].</p><p>Concerns have been raised about severe abdominal pain and bowel perforation in patients with advanced cancer who were receiving <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a> for OIC [<a href="#rid40">40-42</a>]. These concerns led the FDA to issue a warning for clinicians to use caution when administering methylnaltrexone to patients with known or suspected lesions in the intestinal wall, and to stop the drug immediately for worsening of gastrointestinal symptoms [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H1055279875"><span class="h5">Naloxegol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="97147" href="/z/d/drug information/97147.html" rel="external">Naloxegol</a>, a pegylated form of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, appears to be effective against refractory OIC in patients with non-cancer-related pain, without reversal of the analgesic effect; benefit in patients with chronic non-cancer pain is supported by one phase 2 trial and two randomized placebo-controlled phase 3 trials [<a href="#rid44">44,45</a>]. A single prospective nonrandomized study in 124 patients with cancer pain and OIC supports efficacy and safety in those with an inadequate response to laxative therapy [<a href="#rid46">46</a>]. In the United States, naloxegol is approved for treatment of OIC in patients with non-cancer pain. It can be used off-label in the cancer population. The European Medicines Agency (EMA) has approved naloxegol for treatment of OIC without the restriction to non-cancer pain.</p><p>As has been seen with <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a>, cases of gastrointestinal perforation have been reported with <a class="drug drug_general" data-topicid="97147" href="/z/d/drug information/97147.html" rel="external">naloxegol</a> [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H1835345643"><span class="h5">Naldemedine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112482" href="/z/d/drug information/112482.html" rel="external">Naldemedine</a> is an orally active PAMORA. Benefit for OIC was shown in two identically designed, double-blind, placebo-controlled, 12-week phase III trials conducted in patents with non-cancer chronic pain and OIC (COMPOSE 1 and 2) [<a href="#rid48">48</a>]. Responders were defined as those with 9 or more positive response weeks (PRW) out of 12 and three PRW of the last four weeks. A PRW was defined as three or more spontaneous bowel movements per week and an increase of one or more spontaneous bowel movements per week over baseline. COMPOSE 1 enrolled 547 subjects, 274 to naldemedine (0.2 mg orally daily) and 273 to placebo, while COMPOSE 2 enrolled 553 individuals, 277 to the same dose of naldemedine and 276 to placebo. There was a significantly greater proportion of responders with naldemedine (study I, 47.6 versus 34.6 percent; study II, 52.5 versus 33.6 percent). A significantly greater increase in the frequency of spontaneous bowel movements per week from baseline was noted with naldemedine during week 1, and the difference between the two groups persisted throughout the 12-week study period. In both studies, treatment with naldemedine was well tolerated; the only treatment-emergent adverse effects with incidence &gt;5 percent with naldemedine were abdominal pain (17 versus 5 percent with placebo in study I) and diarrhea (18 versus 8 percent with placebo in study I). Naldemedine was not associated with signs or symptoms of opioid withdrawal, and the analgesic effect of the opioid was not significantly affected. Subsequently, two additional randomized controlled trials in patients with chronic non-cancer pain came to similar conclusions [<a href="#rid49">49,50</a>].</p><p class="bulletIndent1">Largely based on the experience from COMPOSE 1 and 2, <a class="drug drug_general" data-topicid="112482" href="/z/d/drug information/112482.html" rel="external">naldemedine</a> was approved in the United States for OIC in adult patients with chronic non-cancer pain [<a href="#rid51">51</a>]. However, efficacy was also shown for naldemedine in the treatment of OIC in patients with cancer in a randomized, placebo-controlled, phase III trial (71 percent responded to 0.2 mg/day compared with 34 percent of the placebo group, using the same response criteria as used in the COMPOSE trials) [<a href="#rid52">52</a>], and the drug can be used off-label in the cancer population. The EMA has approved naldemedine for treatment of OIC without the restriction to non-cancer pain [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H2132365050"><span class="h5">Alvimopan</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9057" href="/z/d/drug information/9057.html" rel="external">Alvimopan</a> is an orally administered PAMORA that is approved in the United States for short-term inpatient management of postoperative ileus in patients undergoing bowel resection. (See  <a class="medical medical_review" href="/z/d/html/8042.html" rel="external">"Postoperative ileus"</a> and  <a class="medical medical_review" href="/z/d/html/15155.html" rel="external">"Measures to prevent prolonged postoperative ileus", section on 'Peripheral acting mu-opioid receptor antagonists'</a>.)</p><p>The benefit of <a class="drug drug_general" data-topicid="9057" href="/z/d/drug information/9057.html" rel="external">alvimopan</a> for OIC was shown in a meta-analysis of four randomized trials (1693 patients, all with non-cancer-related pain [<a href="#rid54">54-57</a>]) in which the relative risk (RR) for continued constipation with alvimopan was 0.71 (95% CI 0.65-0.78) [<a href="#rid30">30</a>]. In one of the trials, active treatment did not increase the requirement for opioid medication or increase pain intensity scores [<a href="#rid56">56</a>]. The drug was specifically not approved for OIC because an earlier unpublished 12-month safety study in patients treated with opioids for chronic pain had shown more reports of myocardial infarction in patients treated with alvimopan than with placebo [<a href="#rid58">58</a>]. Although a causal relationship has not been established, without more information, the use of this drug in the ambulatory setting for OIC in cancer patients cannot be recommended.</p><p class="headingAnchor" id="H110867556"><span class="h5">Other orally administered opioid antagonists</span><span class="headingEndMark"> — </span>Other orally administered opioid antagonists are also available for treatment of refractory OIC.</p><p>Oral <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> (1 to 12 mg), an opioid antagonist, has been used to treat OIC; in a meta-analysis of four placebo-controlled randomized trials (798 patients, predominantly receiving opioids for non-cancer-related pain [<a href="#rid59">59-62</a>]), the RR for continued constipation was significantly lower with naloxone (RR 0.64, 95% CI 0.56-0.78) [<a href="#rid30">30</a>]. However, it is 3 percent bioavailable [<a href="#rid63">63</a>] with oral administration and, for this reason, may reverse systemic opioid effects, potentially worsening pain or inducing withdrawal effects.</p><p>A new <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> sustained-release capsule appears to be safe and efficacious for the treatment of OIC without compromising the desired opioid analgesic effects [<a href="#rid64">64</a>]. However, this formulation is not available or approved in any country as of yet.</p><p>A fixed-ratio combination of immediate-release <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a> plus <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> is available commercially (Targin and Targinact) in Germany, Canada, and some other countries. A long-acting formulation of oxycodone plus naloxone (Targiniq ER) is approved in the United States for treatment of moderate to severe pain for which alternative treatment options are inadequate [<a href="#rid11">11,59</a>]. Although this drug combination has no labeled indication for relief or prevention of OIC in the United States, some countries, such as Canada, have approved the fixed-dose combination for treatment of chronic pain and relief or prevention of OIC in patients who require an opioid. This approval is based on randomized studies demonstrating that in patients with chronic non-malignant pain, oxycodone/naloxone results in better intermediate-term bowel function compared with oxycodone or <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> alone while maintaining pain relief [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H372619492"><span class="h4">Lubiprostone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">Lubiprostone</a> is a type-2 chloride channel activator that induces secretion of fluid in the intestine. Efficacy in OIC has been confirmed in at least three randomized controlled trials [<a href="#rid66">66,67</a>]. In the largest of these trials, 418 patients with chronic non-cancer pain and OIC were randomly assigned to lubiprostone (24 mcg twice daily) or placebo for 12 weeks [<a href="#rid66">66</a>]. Patients receiving lubiprostone had significant improvement in spontaneous bowel movements, abdominal discomfort, straining, constipation severity, and stool consistency. Patients rated lubiprostone effectiveness to be higher than placebo during 11 of the 12 weeks, and side effects were largely tolerable (nausea, lubiprostone 17 versus 6 percent with placebo; diarrhea, 10 versus 3 percent; and abdominal distention, 8 versus 2 percent).</p><p>On the other hand, efficacy for <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">lubiprostone</a> could not be shown in a third identically designed phase III trial of 451 patients with chronic non-cancer pain [<a href="#rid68">68</a>]. The authors performed a pooled analysis of all three trials and concluded that the efficacy of lubiprostone for OIC might be limited to patients receiving non-methadone opioids.</p><p>In the United States, <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">lubiprostone</a> is approved for treatment of OIC in patients receiving opioid therapy for chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (ie, weekly) opioid dose escalation.</p><p class="headingAnchor" id="H784234588"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span>We reserve probiotics for those with severe constipation refractory to other modalities, given limited supporting data regarding efficacy and dose, and lack of federal regulation of available products. Small, randomized, placebo-controlled trials of probiotics in patients with chronic constipation without irritable bowel syndrome and in normal subjects with a tendency toward infrequent stools suggest improvement in defecation frequency and stool consistency [<a href="#rid69">69</a>]. However, a systematic review concluded that until larger studies are performed, there are insufficient data to recommend probiotics in the management of severe constipation [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/2603.html" rel="external">"Probiotics for gastrointestinal diseases", section on 'Constipation'</a>.)</p><p><a class="drug drug_general" data-topicid="86369" href="/z/d/drug information/86369.html" rel="external">Linaclotide</a>, a guanylyl cyclase C agonist, is approved for the treatment of irritable bowel syndrome and chronic idiopathic constipation. It could be considered for a trial in those with OIC. (See  <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">"Management of chronic constipation in adults", section on 'Linaclotide'</a>.)</p><p>In addition, <a class="drug drug_general" data-topicid="83328" href="/z/d/drug information/83328.html" rel="external">prucalopride</a>, a highly selective 5HT4 receptor agonist that acts as a prokinetic in the gut, is approved for treatment of chronic idiopathic constipation; it too may be considered for a trial in those with OIC. (See  <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">"Management of chronic constipation in adults", section on 'Prucalopride'</a>.)</p><p class="headingAnchor" id="H1606843954"><span class="h3">Guidelines from expert groups</span><span class="headingEndMark"> — </span>A 2019 guideline on management of OIC is available from the AGA [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Traditional laxatives should be used as first-line agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PAMORAs should be considered only when traditional laxatives fail.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The committee offered a strong recommendation based on a moderately strong to strong quality of evidence for use of <a class="drug drug_general" data-topicid="97147" href="/z/d/drug information/97147.html" rel="external">naloxegol</a> and <a class="drug drug_general" data-topicid="112482" href="/z/d/drug information/112482.html" rel="external">naldemedine</a>, but it offered only a conditional recommendation based on only a low quality of evidence for use of <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a>. They also pointed out that the costs of naloxegol and naldemedine are substantially lower than that of methylnaltrexone. The committee noted that only two of the five reviewed randomized trials of methylnaltrexone were conducted in non-cancer patients, and they did not review the multiple meta-analyses and network analyses reported above.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is insufficient evidence to support the use of <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">lubiprostone</a> or <a class="drug drug_general" data-topicid="83328" href="/z/d/drug information/83328.html" rel="external">prucalopride</a> for the management of OIC.</p><p></p><p>Recommendations have also been proposed by the American Academy of Pain Medicine (AAPM) [<a href="#rid71">71</a>], the Multinational Association for Supportive Care in Cancer (MASCC) [<a href="#rid72">72</a>], and the European Society for Medical Oncology (ESMO) [<a href="#rid73">73</a>]. The MASCC recommendations do not specify which PAMORA is preferred, and they also support the use of alternative agents, such as <a class="drug drug_general" data-topicid="86369" href="/z/d/drug information/86369.html" rel="external">linaclotide</a>, <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">lubiprostone</a>, or <a class="drug drug_general" data-topicid="83328" href="/z/d/drug information/83328.html" rel="external">prucalopride</a>, in patients who fail to respond to first-line conventional laxatives [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H1663053194"><span class="h2">Narcotic bowel syndrome</span><span class="headingEndMark"> — </span>Narcotic bowel syndrome is a type of opioid-induced bowel dysfunction that is characterized by the seemingly paradoxical development of worsening abdominal pain in the context of escalating or continuous chronic opioid therapy [<a href="#rid74">74</a>]. It is most often described in patients taking opioids for chronic non-cancer pain and in opioid misusers [<a href="#rid75">75-77</a>].</p><p>The underlying pathophysiologic mechanisms are incompletely understood, although centrally mediated opioid-induced hyperalgesia may contribute [<a href="#rid78">78</a>]. (See <a class="local">'Opioid-induced hyperalgesia'</a> below.)</p><p>When a patient who is receiving long-term opioid therapy and has OIC develops abdominal pain, the usual response is to reevaluate the patient for a potentially treatable cause of the pain and modify the laxative regimen. Sometimes, the opioid dose is increased. The term "narcotic bowel syndrome" becomes diagnostically useful if no alternative cause is found and if changes in the laxative regimen are not helpful (or paradoxically increase cramping), particularly if pain increased in tandem with an increase in opioid dose.</p><p>When the diagnosis of narcotic bowel syndrome is appropriate, opioid tapering must be considered [<a href="#rid79">79</a>]. A cornerstone of management is the development of a therapeutic alliance with the patient in the context of symptom validation, detailed education, and mutual agreement on symptom reduction goals, with the ultimate aim of opioid detoxification [<a href="#rid74">74</a>]. Proposed treatments include early incorporation of nonpharmacologic therapies (eg, stress reduction, exercise), opioid-sparing analgesics (eg, antidepressants), laxatives to control transient constipation, and referral for psychologic support. Opioid rotation is often considered as well.</p><p class="headingAnchor" id="H6"><span class="h1">SOMNOLENCE AND MENTAL CLOUDING</span><span class="headingEndMark"> — </span>Opioid therapy can cause somnolence or mental clouding. Typically, sedation is most problematic upon dose initiation or escalation, and most patients develop tolerance within days to weeks. Symptoms are persistent in some patients, particularly in those with other contributing factors such as early dementia or the use of other centrally acting drugs, particularly benzodiazepines. Concurrent use of benzodiazepines and gabapentinoids increases the risk for oversedation, respiratory depression, and death. (See <a class="local">'Respiratory depression'</a> below.)</p><p>The characteristics of opioid-induced somnolence and mental clouding can vary widely. The degree of cognitive impairment ranges from slight inattention or fatigue, to befuddlement, to disorientation, severe memory impairment, or extreme confusion and delirium. Perceptual disorders, which themselves range from increased dreaming and hypnagogic illusions to frank hallucinations, can occur, as can mood disturbances. In this population, mood disturbance is more often negative (irritability, depressed mood, dysphoria) than positive (contentment, euphoria).</p><p>The incidence of cognitive dysfunction in patients receiving chronic opioid therapy is not well characterized. A prospective, multicenter, cross-sectional study of 1915 adult patients with cancer who received opioids for at least three days suggested that possible or definite cognitive dysfunction (as assessed by Mini-Mental State Examination [MMSE]) scores lower than 27 were present in one-third of treated patients [<a href="#rid80">80</a>]. Risk factors for cognitive dysfunction included a diagnosis of lung cancer, daily opioid doses (oral <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> equivalents) of ≥400 mg, older age, low performance status  (<a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">table 4</a>), and time since cancer diagnosis &lt;15 months; the presence of breakthrough pain was associated with better cognitive function. (See  <a class="medical medical_review" href="/z/d/html/14067.html" rel="external">"The mental status examination in adults", section on 'Cognitive screening tests'</a>.)</p><p class="headingAnchor" id="H4023729658"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Like other symptoms associated with opioid therapy, the decision to pursue additional evaluation is a clinical judgment that is influenced by the likelihood that other factors may be contributing. If the relationship of the symptoms to the drug or other factors is clear, further evaluation may not be needed. (See  <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">"Diagnosis of delirium and confusional states"</a>.)</p><p class="headingAnchor" id="H857016330"><span class="h3">Overdose versus side effect</span><span class="headingEndMark"> — </span>Evaluation of the severity and temporal course of the somnolence or cognitive change is important whether or not the opioid is the primary factor responsible for the symptoms and signs or one of several factors. A rapidly evolving decline in consciousness or cognition, or presentation when the symptoms or signs are severe increases the urgency of intervention. Depending on the circumstances, evolving opioid overdose must be considered, which in turn necessitates continuous observation, rapid evaluation for other causes, and consideration of antagonist therapy with <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> should hypoventilation be observed or appear to be imminent. Clinical decisions in this situation rely on the history of opioid consumption and the assessment of somnolence and respiratory pattern; there are no other signs of opioid excess reliable enough to use as an indicator that the opioid is or is not a primary determinant of the condition. Naloxone should not be used unless there is respiratory compromise, and it is important to understand that the clinical improvement that may occur when a symptomatic patient receiving an opioid is given naloxone does not mean that the opioid is the sole factor, or even the major factor, responsible for the patient’s cognitive changes. (See  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment", section on 'Overdose and mortality'</a>.)</p><p>If the patient’s somnolence or change in cognition is rapidly evolving but the respiratory pattern is normal, continuous observation may be necessary, and the opioid should be held until there is greater certainty about the diagnosis and the patient has stabilized. If the opioid is determined to be responsible for this occurrence, the decision to restart therapy should incorporate more cautious dosing and increased monitoring.</p><p>Most patients who experience the side effect of somnolence or cognitive impairment have relatively mild, and slowly evolving or stable symptoms. Evaluation and management in this situation typically occur in the ambulatory environment and do not require the use of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>.</p><p class="headingAnchor" id="H7"><span class="h2">Management</span><span class="headingEndMark"> — </span>A stepwise approach to management of opioid-induced somnolence and mental clouding includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Obvious contributing causes (eg, primary central nervous system [CNS] pathology, metabolic disturbances, dehydration, other drugs) should be addressed and treated if this is feasible and consistent with the goals of care. Nonessential centrally acting medications, especially CNS depressants, should be reduced or eliminated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The opioid regimen should be evaluated. If analgesia is satisfactory, it may be possible to reduce the dose, but this is often limited by worsened pain. The impact of an empiric 25 percent dose reduction on both pain control and side effects is usually clear within a short time frame.</p><p></p><p class="bulletIndent1">On the other hand, if analgesia is unsatisfactory, opioid rotation may be tried, or an adjuvant (coanalgesic) may be initiated in an attempt to achieve an opioid-sparing effect. (See  <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia", section on 'Pain that respond poorly to opioids alone'</a> and  <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)"</a> and  <a class="medical medical_review" href="/z/d/html/2798.html" rel="external">"Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug treatment directed at the symptom (ie, a psychostimulant) may be considered.</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Psychostimulants</span><span class="headingEndMark"> — </span>The potential value of a CNS stimulant to mitigate opioid-induced somnolence or mental clouding is suggested by limited clinical literature and anecdotal experience [<a href="#rid81">81,82</a>]. The largest experience is with <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> for patients with cancer pain and with <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> for patients receiving opioids for non-malignant pain.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methylphenidate</strong> – Benefit for <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> in patients receiving opioids has been suggested in two of three small randomized trials, all of which were conducted in patients with cancer pain [<a href="#rid83">83-85</a>]. A systematic review concluded that this represented weak evidence in support of the use of methylphenidate given that the quality of the negative study was lower than that of the two positive studies [<a href="#rid86">86</a>]. Notably, treatment with methylphenidate may be associated with anxiety, hallucinations, and sweating.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">Methylphenidate</a> is typically initiated at a starting dose of 5 mg in the morning and at noon, or a comparable dose of one of the long-acting modified-release formulations. The dose usually requires titration until benefits occur or side effects supervene [<a href="#rid87">87</a>]. Most patients experience benefit at doses well below 60 mg/day, but some require higher doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modafinil</strong> – <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">Modafinil</a>, a nonamphetamine psychostimulant, appears to cause fewer sympathomimetic side effects than <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> and other psychostimulants. Evidence to support benefit of modafinil to prevent opioid-induced sedation is limited to retrospective reports of patients with pain of non-malignant origin [<a href="#rid88">88-90</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">Modafinil</a> is initiated at 100 to 200 mg/day and may require dose escalation to optimize effects. Most patients require no more than 600 mg/day, and only occasional patients require twice daily, as compared with once daily, dosing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other psychostimulants and cholinesterase inhibitors</strong> – Other psychostimulants that may be beneficial in the setting of opioid-induced sedation include <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">dextroamphetamine</a> [<a href="#rid91">91</a>], <a class="drug drug_general" data-topicid="8667" href="/z/d/drug information/8667.html" rel="external">dexmethylphenidate</a>, <a class="drug drug_general" data-topicid="9260" href="/z/d/drug information/9260.html" rel="external">armodafinil</a>, <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a>, and <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">caffeine</a> [<a href="#rid92">92</a>]. An alternative approach, the use of a cholinesterase inhibitor, <a class="drug drug_general" data-topicid="9383" href="/z/d/drug information/9383.html" rel="external">donepezil</a>, also has been studied but the data are very limited [<a href="#rid93">93,94</a>]. A systematic review of treatment for opioid-related CNS symptoms concluded that the quality of the studies involving dextroamphetamine, caffeine, and donepezil was not sufficient to make any recommendations about their use [<a href="#rid86">86</a>]. These drugs are usually considered only if <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> or <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> are poorly tolerated or contraindicated.</p><p></p><p>The therapeutic effects of psychostimulants sometimes wane over time. Whether this reflects tolerance or symptom progression is unknown, but the phenomenon should be recognized. Dose escalation of the psychostimulant or a switch to an alternative drug may be useful.</p><p>All psychostimulants can produce side effects such as tremulousness, insomnia, anorexia, anxiety, tachycardia, and hypertension. Given the potential for these adverse effects, relative contraindications to the use of psychostimulants include severe insomnia, a psychiatric disorder characterized by anxiety or paranoid ideation, significant cardiac disease, or poorly controlled hypertension. Older patients and those with early dementing illnesses are especially susceptible to untoward psychotomimetic and cognitive disturbance.</p><p>While the available data suggest that the risk of serious cardiovascular problems with psychostimulants is low in adults treated for attention-deficit hyperactivity disorder [<a href="#rid95">95</a>], there are no data on their safety in patients with preexisting arrhythmias, such as stable controlled atrial fibrillation. Consultation with the patient’s cardiologist is advised in such cases to determine whether the findings are sufficiently severe to avoid use of these medications. The cardiovascular effects of psychostimulants in adults are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/118534.html" rel="external">"Attention deficit hyperactivity disorder in adults: Treatment overview", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H2758941232"><span class="h2">Opioid-induced delirium</span><span class="headingEndMark"> — </span>Opioids can contribute to the onset or persistence of delirium. Typically, the opioid is one of several factors that may be etiologically important. Other centrally acting drugs may be involved and worsen delirium through a direct effect (eg, glucocorticoid) or through an effect that augments anti-anticholinergic load. Metabolic disturbances causes by major organ dysfunction or other factors, such as dehydration, also are commonly encountered. If the opioid is perceived as contributing, management may include a trial of a lower dose (eg, dose reduction of 25 to 50 percent) to determine whether this change is associated with worsening pain, a switch to an alternative opioid (ie, opioid rotation), and/or treatment of symptoms with a co-administered neuroleptic.</p><p>In general, clinicians must balance the benefits of using opioids to treat significant pain with the potential for development of opioid-related delirium, as discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4823.html" rel="external">"Delirium and acute confusional states: Prevention, treatment, and prognosis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">OTHER SIDE EFFECTS</span><span class="headingEndMark"> — </span>Numerous other side effects are less common but widely recognized opioid-related problems. This section does not address issues related to opioid abuse, including overdose. (See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management", section on 'Opioid analgesics'</a> and  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment", section on 'Overdose and mortality'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Nausea and vomiting</span><span class="headingEndMark"> — </span>Nausea frequently complicates the initiation of opioid therapy, but tolerance occurs quickly, and persistent nausea is infrequent. When persistent nausea occurs, it is often in the context of other, less well-characterized gastrointestinal symptoms, including dry mouth, reflux, anorexia, early satiety, and abdominal bloating [<a href="#rid96">96</a>].</p><p>Based upon clinical observations, there is much individual variation in the occurrence of nausea and in the response of the individual to different opioid drugs. One patient may experience intense nausea with <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> and none while receiving <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, while the opposite may be observed in a different patient. There have been no comparative studies among the commonly used mu-agonist opioids.</p><p>Opioids have three potentially emetogenic mechanisms: a direct effect on the chemoreceptor trigger zone, enhanced vestibular sensitivity, and delayed gastric emptying [<a href="#rid97">97</a>]. Refractory constipation and stool impaction may be contributory. When impaction is a factor, it should be managed urgently.</p><p>Opioid rotation or a change in route of administration could be considered as a strategy to address chronic nausea. In two small studies, a switch from the oral to the subcutaneous route produced significantly less nausea and vomiting [<a href="#rid98">98,99</a>]. By contrast, there are conflicting data as to the benefit of switching from the oral to the rectal route [<a href="#rid98">98,100-102</a>]. Nevertheless, at least two systematic reviews [<a href="#rid103">103,104</a>] have concluded that there was some weak evidence for changing the opioid or the route of administration in patients with cancer who are experiencing persistent opioid-induced nausea and vomiting. (See  <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia", section on 'Selecting the route of administration'</a> and  <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia", section on 'Pain that respond poorly to opioids alone'</a>.)</p><p>Chronic nausea usually responds to the same group of drug therapies that are used for acute nausea  (<a class="graphic graphic_table graphicRef80259" href="/z/d/graphic/80259.html" rel="external">table 5</a>) [<a href="#rid105">105,106</a>]. The available evidence supports use of a dopamine antagonist, such as <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> or <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> (also a prokinetic drug [<a href="#rid103">103,107</a>]), or a serotonin receptor antagonist, such as <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> [<a href="#rid107">107-109</a>], as usual first-line agents. However, the data are of very low quality, and the choice of antiemetic is either empirical, or based on the presumed underlying mechanism (eg, a prokinetic agent for patients with features of delayed gastric emptying, or an antihistamine antiemetic for a patients with enhanced vestibular sensitivity) [<a href="#rid110">110</a>].</p><p>Although both <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> and <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> can cause extrapyramidal symptoms, metoclopramide has the advantage of causing less sedation and promoting gastric motility. On the other hand, 5-hydroxytryptamine type 3 (5HT3) receptor antagonists have the disadvantage of exacerbating constipation in patients who might already be experiencing opioid-induced gastrointestinal dysmotility. (See  <a class="medical medical_review" href="/z/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a>.)</p><p>If a conventional dopamine antagonist is not tolerated, switching to an atypical antipsychotic agent, such as <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> or <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, also may be considered. A small observational retrospective study found that risperidone 1 mg daily orally [<a href="#rid111">111</a>] decreased refractory nausea and vomiting thought to be due to opioids in patients with advanced cancer. Furthermore, in the setting of chemotherapy-induced nausea and vomiting, olanzapine has been shown to reduce chronic nausea [<a href="#rid112">112</a>]. (See  <a class="medical medical_review" href="/z/d/html/85750.html" rel="external">"Assessment and management of nausea and vomiting in palliative care", section on 'Medications including opioids'</a>.)</p><p>The specific clinical scenario may also suggest potential benefit from other strategies:</p><p class="bulletIndent1"><span class="glyph">●</span>Some patients who experience nausea with movement or nausea associated with vertigo may respond to an anticholinergic drug, such as <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">scopolamine</a>, or an antihistamine, such as <a class="drug drug_general" data-topicid="9597" href="/z/d/drug information/9597.html" rel="external">meclizine</a> [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If nausea follows meals or is accompanied by postprandial vomiting, <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> is an appropriate choice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with epigastric pain or burning should be offered a trial of a proton pump inhibitor, such as <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">pantoprazole</a>, or a histamine 2 (H2) receptor antagonist, such as <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">famotidine</a>.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Myoclonus</span><span class="headingEndMark"> — </span>Myoclonus (brief involuntary contractions of a muscle or group of muscles) may accompany acute encephalopathy of any cause and may occur in association with opioid-induced neurotoxicity. It is often associated with somnolence and mental clouding. The etiology may be multifactorial, with contributions from other drugs and/or metabolic disturbances.</p><p>The available evidence for treatment of myoclonus comes almost exclusively from published case reports. A systematic review concluded that the available data were insufficient to confirm or refute the benefits of any drug for the management of opioid-induced myoclonus [<a href="#rid86">86</a>].</p><p>If treatment is considered, the usual approach is to try a low dose of the benzodiazepine <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> (0.5 mg orally every six to eight hours [<a href="#rid114">114</a>]) or <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> (0.5 to 1 mg orally, sublingually, or intravenously every two to three hours). A trial of an anticonvulsant is rarely considered. A change to another opioid or the addition of an adjuvant analgesic may permit a reduction in opioid dose, relieving the myoclonus. (See  <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Neuroendocrine effects</span><span class="headingEndMark"> — </span>Opioids affect the functioning of the hypothalamic-pituitary-adrenal axis, resulting in increased levels of prolactin, decreased levels of sex hormones, and rarely, secondary adrenal insufficiency [<a href="#rid115">115-117</a>]. (See  <a class="medical medical_review" href="/z/d/html/6637.html" rel="external">"Clinical manifestations of hypopituitarism"</a>.)</p><p>The potential for clinically significant opioid-induced hypogonadism is receiving increased attention [<a href="#rid117">117</a>]. (See  <a class="medical medical_review" href="/z/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a> and  <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a> and  <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">"Evaluation and management of secondary amenorrhea"</a> and  <a class="medical medical_review" href="/z/d/html/7435.html" rel="external">"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p>Hypogonadism may lead to troubling symptoms such as sexual dysfunction, fatigue, or depressed mood, or cause problems such as accelerated bone loss or infertility. If these symptoms or problems are occurring in opioid-treated patients, it is important to recognize the possibility of drug-related toxicity.</p><p>For males, there are conflicting reports as to the benefits of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> replacement therapy. While one review suggests that testosterone replacement therapy is safe and effective for opioid-induced hypogonadism [<a href="#rid118">118</a>], another reveals that the evidence of effectiveness is of very low to low quality and suggests only possible benefit for pain and emotional functioning but no benefit for sleep quality, depressed mood, or sexual or physical functioning [<a href="#rid119">119</a>]. On the other hand, new information is available from an analysis of 21,272 long-term male opioid users receiving treatment in the United States Veterans Health Administration (VHA) who had low free or total testosterone levels, of whom 14,121 received testosterone treatment and 7151 did not [<a href="#rid120">120</a>]. After adjusting for covariates (sociodemographic variables, physical and mental comorbidities, specific medications), long-term opioid users who received testosterone had significantly lower all-cause mortality (hazard ratio [HR] 0.51, 95% CI 0.42-0.61) and a lower incidence of major adverse cardiovascular events (HR 0.58, 95% CI 0.51-0.67), anemia (HR 0.73, 95% CI 0.68-0.79), and femoral or hip fractures (HR 0.68, 95% CI 0.48-0.96) than their counterparts who received opioids only.</p><p>These issues must be considered in context. In particular, their relevance in patients treated with opioids for pain related to active cancer or another advanced illness is unclear. However, many cancer patients report symptoms that could be related to hypogonadism, and these concerns may adversely impact quality of life. Given the recent data discussed above, which are reassuring in terms of risk and suggest potential benefits from <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> replacement, clinicians should assess for these quality of life concerns in males and measure testosterone levels if there is no contraindication to testosterone treatment and the goals of care support an evaluation. If testosterone levels are low and the clinical setting is appropriate, a trial of testosterone treatment is reasonable. Testosterone treatment of male hypogonadism is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p>For females, the data are more limited. Nonetheless, it is reasonable to take a similar approach. Postmenopausal symptoms and symptoms of fatigue, depressed mood, and sexual dysfunction should be assessed if clinically appropriate. If there is no contraindication to estradiol treatment, blood levels of sex hormones should be measured, and a trial of estrogen therapy should be considered if levels are low. (See  <a class="medical medical_review" href="/z/d/html/6640.html" rel="external">"Treatment of hypopituitarism", section on 'LH and FSH deficiency'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Sleep-disordered breathing</span><span class="headingEndMark"> — </span>A syndrome of opioid-induced sleep-disordered breathing is becoming recognized as a risk during long-term opioid therapy. Opioid therapy may exacerbate an existing central or obstructive sleep apnea syndrome or may initiate obstructive sleep apnea in those predisposed by other factors, such as obesity or short neck. Opioid therapy can also be associated with the development of a central or mixed syndrome, even in those without known predisposing factors. Patients with symptoms that may indicated a sleep apnea syndrome, such as daytime somnolence, poor or nonrestorative sleep, significant fatigue or snoring, and patients who have significant risk factors for obstructive sleep apnea, such as obesity, should be treated cautiously with opioids. A concern about sleep-disordered breathing also should lead to very cautious use of cotreatment with centrally acting drugs that also may impact sleep, particularly the benzodiazepines. If the clinical setting is appropriate, the patient with sleep-related symptoms or daytime somnolence can undergo further evaluation.</p><p>The American Academy of Sleep Medicine (AASM) has released a position statement on chronic opioids and sleep, which highlights opioids as a risk factor for respiratory depression during sleep, sleep-disordered breathing, and altered sleep architecture [<a href="#rid121">121</a>]. In-laboratory polysomnography (PSG) is the test of choice to diagnose sleep-disordered breathing due to chronic opioids; supplemental use of carbon dioxide monitoring during PSG is required to detect sleep-related hypoventilation. Positive airway pressure therapy is suggested in symptomatic patients and those with moderate to severe sleep apnea on PSG. This subject is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/97859.html" rel="external">"Sleep-disordered breathing in patients chronically using opioids"</a>.)</p><p class="headingAnchor" id="H3871239225"><span class="h2">Respiratory depression</span><span class="headingEndMark"> — </span>Respiratory depression is commonly considered a serious adverse effect of opioid drugs, but it is rarely a problem when therapy is administered according to accepted guidelines, particularly when dose titration is performed using relatively small increments (25 to 50 percent) and at intervals long enough to observe the effects of a dose at steady state drug concentrations [<a href="#rid122">122-124</a>]. Tolerance usually develops rapidly to this effect, allowing escalation of the dose without clinically significant respiratory effects. (See  <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia", section on 'Dose titration'</a>.)</p><p>Greater caution is needed when opioids are administered in the setting of cardiopulmonary disorders, a sleep apnea syndrome, or some other serious comorbidity that may limit ventilatory reserve, or when the opioid is combined with a sedative-hypnotic or a gabapentinoid:</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent use of benzodiazepines in opioid-treated patients increases the risk of respiratory depression and other serious adverse events [<a href="#rid125">125</a>]. In 2016, the US Food and Drug Administration (FDA) issued a safety communication and now has a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or&amp;token=XVPnuwuy%2BkJs1YE4fUwcfarAoiYA5RL7yKnXHlwSrImu1xUVFc14mNj0qbl4Rt1MOLkx38kRylW3pqZXp7jrp67sQFI5uf9rirc%2BKC77YT%2Fz84vIwIgN%2F5u4%2FeKK2p5LZ8kwpPreZCJy0ZwUUpm%2B7UP8K24AHlMW0LDF%2F2Hacy8%3D&amp;TOPIC_ID=2800" target="_blank">new boxed warning</a> against the combined use of opioids and benzodiazepines or other central nervous system (CNS) depressants due to increased risk of respiratory depression and death. Despite this warning, the concurrent use of opioids with benzodiazepines or nonbenzodiazepine sedatives continues to be frequent, at least among patients with cancer [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> enhance the CNS depressive effects of other centrally-acting drugs, including opioids, and there is an increased risk of oversedation, respiratory depression, or a serious adverse consequence (including death) when gabapentin or pregabalin is added to an opioid regimen [<a href="#rid127">127,128</a>]. Based on review of available pharmacovigilance data, in 2020, the FDA mandated revisions to the labeling regarding the risk of severe and life-threatening respiratory depression with use of gabapentinoids, particularly in combination with CNS depressants (eg, opioids), in those with underlying respiratory disease and in older adults [<a href="#rid129">129</a>].</p><p></p><p>Even in the latter setting, however, cautious selection of the initial dose and conservative incremental dose titration limit the risk of respiratory depression. (See <a class="local">'Sleep-disordered breathing'</a> above.)</p><p>Among patients receiving opioids for cancer pain, it is common for staff to attribute any respiratory problem to the opioid. However, opioids produce somnolence and slowed respirations; respiratory distress that is associated with tachypnea and anxiety is never a primary opioid event.</p><p class="headingAnchor" id="H1561676208"><span class="h3">Naloxone</span><span class="headingEndMark"> — </span>Administration of the short-acting opioid antagonist <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> can reverse opioid-induced respiratory depression. The FDA recommends that health care professionals discuss the availability of naloxone with all patients when prescribing opioid pain relievers. Naloxone is available over the counter or can be prescribed to patients.</p><p>The discussion about <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> should describe its ability to rapidly reverse opioid-induced hypoventilation while pointing out that opioid-treated patients who receive a naloxone dose could have adverse effects such as a severe flare of pain or symptoms and signs of acute withdrawal. Patients should be told that naloxone is not to be self-administered unless an excessive opioid dose has been taken and the goal is to prevent the effects of this dose from occurring. Families should be told that naloxone is used to treat slowed and shallow respirations. If the clinician assesses the patient as having risk factors for respiratory compromise (eg, severe cardiac or pulmonary disease, concomitant use of benzodiazepines or other medicines that depress the CNS, history of opioid use disorder or previous opioid overdose), sharing this information should be considered to encourage the family to monitor the patient appropriately [<a href="#rid130">130</a>]. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids", section on 'Preventing lethal overdose'</a>.)</p><p>Clinicians should note the following about the use of <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> in patients with opioid-treated chronic pain:</p><p class="bulletIndent1"><span class="glyph">●</span>It is essential to recognize that partial reversal of respiratory disturbances by <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> in an opioid-treated patient does not mean that the opioid is the primary cause of the problem, particularly if respiratory problems developed during a period of relatively stable dosing. Regardless of a naloxone response, a search for a concurrent acute process (eg, pulmonary embolism, pneumonia), which may have combined with subclinical opioid effects, is often appropriate in the cancer population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> should not be given to somnolent but easily arousable patients, unless there is significant slowing of the respiratory rate or the assessment suggests that the opioid effect may be rapidly evolving. If the opioid dose and the timing of the last several doses is known, the patient is past the peak concentration of the drug, and the severity of respiratory compromise is not severe, it is best not to treat with naloxone, but rather to withhold further opioid doses until the respiratory rate rises or pain returns.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> should be reserved for symptomatic respiratory depression, which is usually defined as obtundation combined with a respiratory rate of less than 8 breaths per minute. The risks of precipitating a withdrawal syndrome associated with the use of naloxone relatively contraindicate its use in other situations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> is given due to concern about the severity of respiratory compromise, the treatment goal should be reversal of the respiratory effects and <strong>not</strong> a normal level of consciousness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When clinicians administer parenteral <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> to opioid-treated patients in the inpatient setting, it is best to administer the drug using small bolus injections of dilute solution (ie, by diluting a 0.4 mg [1 mL] ampule with 9 mL of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> for a total volume of 10 mL, thus creating a 0.04 mg/mL concentration), which should be titrated against respiratory rate. This approach reduces the risk of pain and withdrawal. Repeated doses of 1 to 2 mL are often necessary every 45 minutes to an hour, as naloxone's half-life is shorter than that of most opioids. Patients receiving sustained-release opioid formulations or long half-life drugs (eg, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9556" href="/z/d/drug information/9556.html" rel="external">levorphanol</a>) may require a naloxone infusion to prevent recurrence of respiratory depression. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the community setting, <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> usually is given nasally, but can be given subcutaneously (using a naloxone autoinjector "pen"), or intramuscularly if there is a delay in securing intravenous access. When given by these routes, the dose is usually standardized by the delivery device, there is slower absorption and delayed elimination, making the drug much more difficult to titrate. (See  <a class="medical medical_review" href="/z/d/html/99945.html" rel="external">"Prevention of lethal opioid overdose in the community"</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Pruritus</span><span class="headingEndMark"> — </span>Pruritus is observed in 2 to 10 percent of patients receiving chronic opioids [<a href="#rid131">131</a>]. The mechanism is uncertain [<a href="#rid132">132</a>]. Although <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> is reported to cause histamine release from mast cells, other opioids (ie, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">sufentanil</a>, and <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">oxymorphone</a>) are less likely to produce histamine release, yet they are still associated with pruritus [<a href="#rid106">106,133,134</a>]. There is increasing evidence that opioid-induced pruritus is mediated through central mu-opioid receptors [<a href="#rid135">135</a>].</p><p>There are no prospective studies on the treatment of opioid-induced pruritus. Despite the controversy as to the role of histamine in opioid-induced pruritus, antihistamines are commonly used as first-line agents, with varying degrees of success [<a href="#rid106">106,132</a>]. Based upon anecdotal experience, some patients report improvement with daily administration of one of the nonsedating antihistamines, such as <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">loratadine</a>, <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a>, or <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">fexofenadine</a>; there is no information about drug-selective effects within this group of agents. Some patients prefer using <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> two or three times per day. Anecdotal experience also suggests benefit from <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> [<a href="#rid136">136</a>], and <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> may be tried empirically. Another option is opioid rotation [<a href="#rid137">137</a>].</p><p>Low doses of opioid antagonists (eg, <a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">nalmefene</a> 10 to 25 mcg intravenously, <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">nalbuphine</a> 1 to 5 mg intravenously/intramuscularly) are effective for treatment of pruritus in patients with non-cancer pain receiving short-term opioids in the postoperative setting, without reversal of opioid analgesia [<a href="#rid132">132,138,139</a>]. However, long-term use of opioid antagonists in patients with cancer pain who are experiencing prolonged opioid-induced pruritus has not been investigated [<a href="#rid138">138</a>].</p><p class="headingAnchor" id="H19382030"><span class="h2">Allergic reaction</span><span class="headingEndMark"> — </span>True opioid allergy is very rare, but both contact dermatitis and systemic hypersensitivity have been reported. Based upon theoretical considerations, it is commonly taught that a patient who continues to need an opioid after demonstrating an allergy to <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> or a semisynthetic opioid (eg, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> or <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>) should be considered for a trial of one of the synthetic opioids (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> or <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>), along with coadministration of a histamine antagonist and a glucocorticoid. However, there is no evidence that cross sensitivity is reduced by this maneuver as compared with a switch to another alkaloid or semisynthetic opioid.</p><p class="headingAnchor" id="H10942457"><span class="h2">Urinary retention</span><span class="headingEndMark"> — </span>Opioids can cause urinary retention. This effect, which is more common in males, may be due to a combination of reduced bladder tone and increased contraction in the urinary bladder sphincter [<a href="#rid140">140-142</a>]. Although coadministration of a nonopioid analgesic therapy that has opioid-sparing effects could presumably reduce the risk of dose-dependent side effects, concomitant nonsteroidal anti-inflammatory drug (NSAID) therapy has not been shown to impact positively on the risk of urinary retention</p><p>If acute urinary retention occurs, catheterization of the bladder may be necessary. The dose of the opioid should be lowered and an effort should be made to reduce or eliminate drugs that may be contributing, such as drugs with anticholinergic effects.</p><p>Opioid antagonists, including low-dose <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, are effective in reversing urinary retention in the context of acute pain management, but they also may reverse analgesia [<a href="#rid143">143</a>]. Peripherally acting mu-opioid receptor antagonists (PAMORAs) such as <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a> and mixed agonist-antagonist drugs such as <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">nalbuphine</a> may be effective [<a href="#rid144">144-146</a>], but the evidence of benefit from these classes is very limited. Anecdotally, some patients appear to respond to drugs used to treat urinary retention related to prostatic hypertrophy, such as the alpha-1 blockers <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">doxazosin</a> or <a class="drug drug_general" data-topicid="9654" href="/z/d/drug information/9654.html" rel="external">tamsulosin</a>. (See  <a class="medical medical_review" href="/z/d/html/6891.html" rel="external">"Medical treatment of benign prostatic hyperplasia", section on 'Alpha-adrenergic receptor blockers for most patients'</a>.)</p><p class="headingAnchor" id="H620659973"><span class="h2">Infection risk</span><span class="headingEndMark"> — </span>Preclinical studies have found that some opioids (especially <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, and <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) have immunosuppressive properties, including reduced natural killer cell cytotoxicity and impairment of neutrophil chemotaxis [<a href="#rid147">147-150</a>]. The relationship between opioid use and infection risk in humans has been examined in four epidemiologic studies, all of which suggest that prescription opioids are associated with an increased risk of serious infection [<a href="#rid151">151-154</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study in which immunocompetent adults aged 65 to 94 with community-acquired pneumonia, as identified through health plan records, were compared with matched controls (for age, sex, and calendar year), current opioid use was associated with a 38 percent greater risk for community-acquired pneumonia compared with nonuse (odds ratio [OR] 1.38, 95% CI 1.08-1.76) [<a href="#rid151">151</a>]. Risk was highest for opioids characterized as immunosuppressive based upon preclinical studies (ie, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> but not <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a> or <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>) and for use of long-acting opioids (OR 3.43, 95% CI 1.44-8.21) but not short-acting opioids (OR 1.27, 95% CI 0.98-1.64).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional evidence for an association between opioids and infection comes from a case-control study conducted in a Tennessee Medicaid population [<a href="#rid153">153</a>]. The 1233 case patients with laboratory-confirmed pneumococcal disease (pneumonia or another infection with isolation of <em>Streptococcus pneumoniae</em> from a normally sterile site, such as the blood or cerebrospinal fluid) aged five and older were matched with 24,300 control participants by diagnosis date, age, and county of residence. Opioid use was measured based on pharmacy prescription records. Results were adjusted for many potential confounders, including markers of frailty. Individuals with invasive pneumococcal disease had greater odds than controls of being current opioid users (adjusted odds ratio [aOR] 1.62, 95% CI 1.36-1.92). Associations were strongest for long-acting opioids (aOR 1.87, 95% CI 1.24-2.82), high-potency opioids (<a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">hydromorphone</a>, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>), and higher opioid doses (especially ≥90 morphine milligram equivalents per day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate analysis using the same population of Tennessee Medicaid enrollees 18 years of age or older who were initiating long-acting opioids, hospitalization rates for serious infection were compared among 22,811 opioid users who received <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">oxymorphone</a>, or <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a> and 61,240 patients who received <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, or <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> [<a href="#rid154">154</a>]. The former group had a significantly lower infection rate (adjusted incidence rate ratio [aIRR] 0.78, 95% CI 0.66-0.91), and in a comparison across opioids, oxycodone users had a lower rate of infection than did morphine users (aIRR 0.73, 95% CI 0.60-0.89).</p><p></p><p>Taken together, these studies support the view that certain opioids may increase the risk of some serious infections, an outcome that appears consistent with preclinical studies that demonstrate the potential for opioid-related immunosuppressive effects. Additional studies are needed to confirm these observations and determine whether risk varies with specific patient characteristics or different types of pathogens. At present, it is reasonable for clinicians to consider an increased risk of serious infection as a potential adverse opioid effect. Based on the information available, this risk may be relatively higher with <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, and <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, but additional studies will be needed to clarify the clinical implications of these data.</p><p class="headingAnchor" id="H2493358003"><span class="h2">Weight gain and abnormal glycemic control</span><span class="headingEndMark"> — </span>Studies of patients receiving <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> therapy for addiction have noted an association between this opioid and weight gain [<a href="#rid155">155-163</a>]. Opioid therapy in both this population and those treated for pain can lead to abnormal glycemic control; both hyperglycemia and hypoglycemia have been observed [<a href="#rid164">164</a>]. For patients with opioid addiction, loss of glycemic control may be related, in part, to a heightened taste preference for sweet foods, a slowing of gastric motility, delayed absorption of glucose, and a delayed insulin response [<a href="#rid155">155,165,166</a>]. Further studies are needed to characterize this potential for opioid-induced change in glycemic control and to determine the extent to which it is clinically relevant in patients with pain, many of whom have prediabetic conditions or frank diabetes. Given the limitations in the extant data, there are presently no specific guidelines related to this potential risk.</p><p class="headingAnchor" id="H1335116040"><span class="h2">Opioid-induced hyperalgesia</span><span class="headingEndMark"> — </span>In the laboratory, opioid-induced hyperalgesia (OIH) is a well-established, easily reproducible state characterized by an exaggerated response to noxious stimuli or the occurrence of nociceptive responses to non-noxious stimuli. This state can be produced by exposure to opioids and preclinical studies have investigated the factors that can modulate OIH development, as well as the underlying cellular and molecular mechanisms [<a href="#rid167">167-170</a>].</p><p>Whether or not OIH is a clinically relevant phenomenon continues to be debated. Although studies in those with addiction and in human volunteers that demonstrate different nociceptive profiles than those in opioid-naïve patients suggest that the phenomenon occurs in humans and may contribute to the overall response to opioid therapy, this conclusion has been questioned based on the populations studied and the methodologies employed [<a href="#rid171">171-173</a>].</p><p>If OIH occurs, it would be characterized by a paradoxical response, whereby a patient receiving opioids for the treatment of pain may actually become more sensitive to certain painful stimuli and, in some cases, experience pain from ordinarily non-painful stimuli (allodynia) [<a href="#rid174">174</a>]. Although solid evidence for the existence of OIH in patients with chronic non-cancer or cancer-related pain is lacking [<a href="#rid175">175</a>], clinical observations suggest that it may be important, at least in some patients or some clinical settings [<a href="#rid167">167,168,173,176</a>]. A systematic review of the evidence for OIH in humans concluded that OIH was evident in patients after chronic opioid exposure, but that the findings were dependent on both the pain stimulus and assessment measures [<a href="#rid176">176</a>]. Anecdotal experience suggests that rare patients receiving escalating doses of an opioid may develop increasing pain and sensitivity of the skin in association with mental clouding and myoclonus; in the absence of other causes, this presentation suggests OIH, particularly if an improvement in pain follows opioid dose reduction. Cases such as this support the view that the experimental phenomenon of OIH may have a clinical correlate, which manifests rarely.</p><p>When individual patients demonstrate a loss of opioid effect in the absence of progressive illness (ie, develop analgesic tolerance), or develop a syndrome of worsening or more-diffuse pain with tremulousness and, possibly, confusion during a period of aggressive opioid escalation, an element of OIH may be occurring. Diagnosis may be complicated if this occurs in association with delirium and the patient is observed to become seemingly more distressed by pain as extra boluses of opioids are given. The diagnosis of OIH (and possibly delirium) should be considered in all patients with worsening or more-diffuse pain during a period of aggressive opioid escalation.</p><p>There is no well-established treatment for OIH [<a href="#rid177">177</a>]. When suspected, it is reasonable to consider opioid rotation [<a href="#rid178">178</a>] or the use of a nonopioid strategy for pain control.</p><p class="headingAnchor" id="H895629775"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115341.html" rel="external">"Society guideline links: Constipation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/119531.html" rel="external">"Society guideline links: Palliative care"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/119434.html" rel="external">"Society guideline links: Cancer pain"</a>.)</p><p class="headingAnchor" id="H26635757"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16249.html" rel="external">"Patient education: Managing pain when you have cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioid-induced constipation</strong> – The most common and persistent side effect from chronic opioid use is opioid-induced constipation (OIC). (See <a class="local">'Opioid bowel dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diagnosis is based on clinical history, physical examination (including rectal examination when appropriate), and limited diagnostic studies, as clinically indicated. Diagnostic criteria are available (the Rome-IV criteria). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest prophylactic therapy for all patients at the time of opioid initiation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We use daily administration of a contact cathartic such as <a class="drug drug_general" data-topicid="10260" href="/z/d/drug information/10260.html" rel="external">senna</a>, with or without a stool softener, or an osmotic laxative  (<a class="graphic graphic_table graphicRef73845" href="/z/d/graphic/73845.html" rel="external">table 2</a>). (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who develop OIC despite prophylaxis, we suggest additional treatment with conventional laxatives rather than immediately starting a prescription drug (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For most patients, we switch to a different laxative than was used for prophylaxis, with dose escalation as tolerated  (<a class="graphic graphic_table graphicRef60646" href="/z/d/graphic/60646.html" rel="external">table 1</a>). We avoid <a class="drug drug_general" data-topicid="9543" href="/z/d/drug information/9543.html" rel="external">lactulose</a> in lactose-intolerant patients, and restrict use of a stool softener to patients with hard, dry stools. We reserve probiotics for those with severe constipation refractory to other modalities, given limited supporting data regarding efficacy and dose, and lack of federal regulation of available products. (See <a class="local">'Initial management'</a> above and <a class="local">'Other therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have passed no stool in several days and who have no evidence of bowel obstruction or ileus may require manual disimpaction. Once an impaction has been ruled out or cleared, laxative therapy may be started.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased consumption of fluids and soluble dietary fiber and increased physical activity may help some patients  (<a class="graphic graphic_table graphicRef60646" href="/z/d/graphic/60646.html" rel="external">table 1</a>). Fiber should not be increased if the patient is debilitated, bowel obstruction is suspected, or hydration cannot be maintained. (See <a class="local">'Initial management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with refractory OIC who do not have a bowel obstruction, we suggest a trial of a PAMORA (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). The choice of agent is empiric, but experience is greatest with subcutaneous <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a>. (See <a class="local">'Management of refractory opioid-induced constipation'</a> above.)</p><p></p><p class="bulletIndent2">If an oral agent is preferred, options include <a class="drug drug_general" data-topicid="97147" href="/z/d/drug information/97147.html" rel="external">naloxegol</a>, oral <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a>, or <a class="drug drug_general" data-topicid="112482" href="/z/d/drug information/112482.html" rel="external">naldemedine</a>. Another alternative is <a class="drug drug_general" data-topicid="86369" href="/z/d/drug information/86369.html" rel="external">linaclotide</a>. (See <a class="local">'Other therapies'</a> above.)</p><p></p><p class="bulletIndent2">Clinicians should use caution when administering PAMORAS to patients with known or suspected lesions in the intestinal wall, given the rare serious side effects observed with <a class="drug drug_general" data-topicid="9444" href="/z/d/drug information/9444.html" rel="external">methylnaltrexone</a>, and should stop the drug immediately for worsening of gastrointestinal symptoms. (See <a class="local">'Methylnaltrexone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sedation and mental clouding</strong> – Opioid therapy can cause somnolence or mental clouding, which typically wanes over a period of days or weeks but may persist. A stepwise treatment approach includes (see <a class="local">'Somnolence and mental clouding'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assess and treat for contributing causes, if consistent with the goals of care. Reduce or eliminate concomitant use of centrally acting medications, especially central nervous system depressants.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If analgesia is satisfactory, an empiric trial of opioid dose reduction is a reasonable first step. If analgesia is unsatisfactory, options include opioid rotation, or administration of a coanalgesic to achieve an opioid-sparing effect. Another option is an empiric trial of a psychostimulant such as <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> or <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a>. (See <a class="local">'Psychostimulants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other side effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nausea frequently complicates opioid initiation, but it is infrequently persistent. Options include a lower opioid dose, opioid rotation, or a change in the route of administration. Patients who do not respond to these approaches should be evaluated for other etiologies and the condition, if identified, should be treated. Otherwise, we treat empirically with an antiemetic  (<a class="graphic graphic_table graphicRef80259" href="/z/d/graphic/80259.html" rel="external">table 5</a>). (See <a class="local">'Nausea and vomiting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Therapeutic options for myoclonus include <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> 0.5 mg orally every six to eight hours, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 0.5 to 1 mg orally, sublingually, or IV every two to three hours, an anticonvulsant, or opioid rotation. (See <a class="local">'Myoclonus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with symptomatic hypogonadism should be assessed for the risks and potential benefits of hormone replacement therapy. (See <a class="local">'Neuroendocrine effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Opioids can worsen preexisting sleep apnea syndrome, precipitate obstructive sleep apnea in predisposed patients, or cause central or mixed sleep apnea. Patients with suspected sleep-related symptoms or daytime somnolence should undergo further evaluation with polysomnography (PSG). (See <a class="local">'Sleep-disordered breathing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory depression is rarely a problem when opioids are administered according to accepted guidelines. Clinicians should discuss with patients and caregivers whether it would be appropriate to coprescribe a <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> "pen" or inhaler to have at home on an as needed basis. (See <a class="local">'Respiratory depression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Opioid-induced pruritus is uncommon but distressing. Therapeutic options include antihistamines, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, or opioid rotation. (See <a class="local">'Pruritus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Opioid-induced hyperalgesia should be considered when worsening pain and tremulousness, often with cognitive impairment, is occurring with opioid dose escalation. Therapeutic options include opioid rotation or a switch to a nonopioid analgesic. (See <a class="local">'Opioid-induced hyperalgesia'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007; 5:1126.</a></li><li><a class="nounderline abstract_t">Poulsen JL, Brock C, Olesen AE, et al. Evolving paradigms in the treatment of opioid-induced bowel dysfunction. Therap Adv Gastroenterol 2015; 8:360.</a></li><li><a class="nounderline abstract_t">Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother 2009; 23:231.</a></li><li><a class="nounderline abstract_t">Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag 2009; 5:137.</a></li><li><a class="nounderline abstract_t">Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009; 13:737.</a></li><li><a class="nounderline abstract_t">Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13:254.</a></li><li><a class="nounderline abstract_t">van Seventer R, Smit JM, Schipper RM, et al. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003; 19:457.</a></li><li><a class="nounderline abstract_t">Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997; 35:25.</a></li><li><a class="nounderline abstract_t">Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 2009; 25:172.</a></li><li><a class="nounderline abstract_t">Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008; 11:492.</a></li><li><a class="nounderline abstract_t">Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012; 26:50.</a></li><li><a class="nounderline abstract_t">Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016; 150:1393.</a></li><li><a class="nounderline abstract_t">Sikirov D. Comparison of straining during defecation in three positions: results and implications for human health. Dig Dis Sci 2003; 48:1201.</a></li><li><a class="nounderline abstract_t">Hari Krishnan R. A review on squat-assist devices to aid elderly with lower limb difficulties in toileting to tackle constipation. Proc Inst Mech Eng H 2019; 233:464.</a></li><li><a class="nounderline abstract_t">Agra Y, Sacristán A, González M, et al. Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J Pain Symptom Manage 1998; 15:1.</a></li><li><a class="nounderline abstract_t">Hawley P, MacKenzie H, Gobbo M. PEG vs. sennosides for opioid-induced constipation in cancer care. Support Care Cancer 2020; 28:1775.</a></li><li><a class="nounderline abstract_t">Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol 1997; 37:904.</a></li><li><a class="nounderline abstract_t">Wirz S, Nadstawek J, Elsen C, et al. Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. Eur J Cancer Care (Engl) 2012; 21:131.</a></li><li><a class="nounderline abstract_t">Twycross RG, McNamara P, Schuijt C, et al. Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study. Palliat Med 2006; 20:419.</a></li><li><a class="nounderline abstract_t">Candy B, Jones L, Larkin PJ, et al. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev 2015; :CD003448.</a></li><li><a class="nounderline abstract_t">Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011; 60:209.</a></li><li><a class="nounderline abstract_t">Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011; :CD003448.</a></li><li><a class="nounderline abstract_t">Teuri U, Vapaatalo H, Korpela R. Fructooligosaccharides and lactulose cause more symptoms in lactose maldigesters and subjects with pseudohypolactasia than in control lactose digesters. Am J Clin Nutr 1999; 69:973.</a></li><li><a class="nounderline abstract_t">Bharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation. Gastroenterology 2013; 144:218.</a></li><li><a class="nounderline abstract_t">Tarumi Y, Wilson MP, Szafran O, Spooner GR. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage 2013; 45:2.</a></li><li><a class="nounderline abstract_t">Ouyang R, Li Z, Huang S, et al. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis. Pain Med 2020; 21:3224.</a></li><li><a class="nounderline abstract_t">Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology 2019; 156:218.</a></li><li><a class="nounderline abstract_t">Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12:371.</a></li><li><a class="nounderline abstract_t">Candy B, Jones L, Vickerstaff V, et al. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. Cochrane Database Syst Rev 2022; 9:CD006332.</a></li><li><a class="nounderline abstract_t">Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol 2013; 108:1566.</a></li><li><a class="nounderline abstract_t">Sridharan K, Sivaramakrishnan G. Drugs for Treating Opioid-Induced Constipation: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials. J Pain Symptom Manage 2018; 55:468.</a></li><li><a class="nounderline abstract_t">Nee J, Zakari M, Sugarman MA, et al. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16:1569.</a></li><li><a class="nounderline abstract_t">Sridharan K. Author's Response. J Pain Symptom Manage 2018; 55:e9.</a></li><li><a class="nounderline abstract_t">Dutka J, Lowe SS, Michaud M, Watanabe S. Long-term use of methylnaltrexone for the management of constipation in advanced cancer. J Support Oncol 2009; 7:177.</a></li><li><a class="nounderline abstract_t">Webster LR, Michna E, Khan A, et al. Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial. Pain Med 2017; 18:1496.</a></li><li><a class="nounderline abstract_t">Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358:2332.</a></li><li><a class="nounderline abstract_t">Rauck R, Slatkin NE, Stambler N, et al. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Pract 2017; 17:820.</a></li><li><a class="nounderline abstract_t">Webster L, Peppin J, Harper J, Israel R. (480) Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain. J Pain 2016; 17:S94.</a></li><li><a class="nounderline abstract_t">Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. JAMA 2000; 284:1383.</a></li><li><a class="nounderline abstract_t">Centeno C, Carranza O, Zuriarrain Y, et al. A prospective study of methylnaltrexone for opioid-induced constipation in advanced illness: should we use it or not? J Pain Symptom Manage 2013; 46:e1.</a></li><li><a class="nounderline abstract_t">Slatkin NE, Lynn R, Su C, et al. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage 2011; 42:754.</a></li><li><a class="nounderline abstract_t">Watkins JL, Eckmann KR, Mace ML, et al. Utilization of methylnaltrexone (relistor) for opioid-induced constipation in an oncology hospital. P T 2011; 36:33.</a></li><li class="breakAll">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99 (Accessed on October 07, 2020).</li><li><a class="nounderline abstract_t">Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014; 370:2387.</a></li><li><a class="nounderline abstract_t">Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013; 154:1542.</a></li><li><a class="nounderline abstract_t">Lemaire A, Pointreau Y, Narciso B, et al. Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation. Support Care Cancer 2021; 29:7577.</a></li><li class="breakAll">MOVANTIK (naloxegol) tablets, for oral use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204760s009lbl.pdf (Accessed on April 16, 2020).</li><li><a class="nounderline abstract_t">Hale M, Wild J, Reddy J, et al. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol 2017; 2:555.</a></li><li><a class="nounderline abstract_t">Webster LR, Yamada T, Arjona Ferreira JC. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Med 2017; 18:2350.</a></li><li><a class="nounderline abstract_t">Webster LR, Nalamachu S, Morlion B, et al. Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain 2018; 159:987.</a></li><li class="breakAll">Symproic (naldemedine), 0.2 mg oral tablets. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208854Orig1s000ltr.pdf (Accessed on March 30, 2017).</li><li><a class="nounderline abstract_t">Katakami N, Harada T, Murata T, et al. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. J Clin Oncol 2017; 35:3859.</a></li><li class="breakAll">Naldemedine (tosylate). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-001893-PIP01-15/pip_001533.jsp&amp;mid=WC0b01ac058001d129 (Accessed on March 30, 2017).</li><li><a class="nounderline abstract_t">Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992; 52:90.</a></li><li><a class="nounderline abstract_t">Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996; 10:135.</a></li><li><a class="nounderline abstract_t">Jansen JP, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011; 12:185.</a></li><li><a class="nounderline abstract_t">Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial. J Pain 2005; 6:184.</a></li><li class="breakAll">Alvimopan prescribing information available online at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77a67dc6-35d3-48ff-9d18-292d4d442f70 (Accessed on October 15, 2014).</li><li><a class="nounderline abstract_t">Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008; 24:3503.</a></li><li><a class="nounderline abstract_t">Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009; 10:531.</a></li><li><a class="nounderline abstract_t">Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23:48.</a></li><li><a class="nounderline abstract_t">Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009; 13:56.</a></li><li><a class="nounderline abstract_t">Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012; 50:360.</a></li><li><a class="nounderline abstract_t">Sanders M, Jones S, Löwenstein O, et al. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects. Pain Med 2015; 16:1540.</a></li><li><a class="nounderline abstract_t">Huang L, Zhou JG, Zhang Y, et al. Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Pain Symptom Manage 2017; 54:737.</a></li><li><a class="nounderline abstract_t">Cryer B, Katz S, Vallejo R, et al. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014; 15:1825.</a></li><li><a class="nounderline abstract_t">Jamal MM, Adams AB, Jansen JP, Webster LR. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol 2015; 110:725.</a></li><li><a class="nounderline abstract_t">Spierings ELH, Drossman DA, Cryer B, et al. Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes. Pain Med 2018; 19:1184.</a></li><li><a class="nounderline abstract_t">Miller LE, Ouwehand AC, Ibarra A. Effects of probiotic-containing products on stool frequency and intestinal transit in constipated adults: systematic review and meta-analysis of randomized controlled trials. Ann Gastroenterol 2017; 30:629.</a></li><li><a class="nounderline abstract_t">Dimidi E, Christodoulides S, Fragkos KC, et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014; 100:1075.</a></li><li><a class="nounderline abstract_t">Müller-Lissner S, Bassotti G, Coffin B, et al. Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline. Pain Med 2017; 18:1837.</a></li><li><a class="nounderline abstract_t">Davies A, Leach C, Caponero R, et al. MASCC recommendations on the management of constipation in patients with advanced cancer. Support Care Cancer 2020; 28:23.</a></li><li><a class="nounderline abstract_t">Larkin PJ, Cherny NI, La Carpia D, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29:iv111.</a></li><li><a class="nounderline abstract_t">Farmer AD, Gallagher J, Bruckner-Holt C, Aziz Q. Narcotic bowel syndrome. Lancet Gastroenterol Hepatol 2017; 2:361.</a></li><li><a class="nounderline abstract_t">Choung RS, Locke GR 3rd, Zinsmeister AR, et al. Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. Am J Gastroenterol 2009; 104:1199.</a></li><li><a class="nounderline abstract_t">Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010; 22:424.</a></li><li><a class="nounderline abstract_t">Ahmadi B, Arab P, Zahedi MJ, et al. Prevalence of narcotic bowel syndrome in opioid abusers in iran. Middle East J Dig Dis 2014; 6:208.</a></li><li><a class="nounderline abstract_t">Keefer L, Drossman DA, Guthrie E, et al. Centrally Mediated Disorders of Gastrointestinal Pain. Gastroenterology 2016.</a></li><li><a class="nounderline abstract_t">Drossman D, Szigethy E. The narcotic bowel syndrome: a recent update. Am J Gastroenterol Suppl 2014; 2:22.</a></li><li><a class="nounderline abstract_t">Kurita GP, Sjøgren P, Ekholm O, et al. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol 2011; 29:1297.</a></li><li><a class="nounderline abstract_t">Reissig JE, Rybarczyk AM. Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann Pharmacother 2005; 39:727.</a></li><li><a class="nounderline abstract_t">Rozans M, Dreisbach A, Lertora JJ, Kahn MJ. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 2002; 20:335.</a></li><li><a class="nounderline abstract_t">Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995; 3:135.</a></li><li><a class="nounderline abstract_t">Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992; 48:163.</a></li><li><a class="nounderline abstract_t">Bruera E, Chadwick S, Brenneis C, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71:67.</a></li><li><a class="nounderline abstract_t">Stone P, Minton O. European Palliative Care Research collaborative pain guidelines. Central side-effects management: what is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus? Palliat Med 2011; 25:431.</a></li><li><a class="nounderline abstract_t">Bruera E, Brenneis C, Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 1989; 4:3.</a></li><li><a class="nounderline abstract_t">Cox JM, Pappagallo M. Modafinil: a gift to portmanteau. Am J Hosp Palliat Care 2001; 18:408.</a></li><li><a class="nounderline abstract_t">Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003; 4:135.</a></li><li><a class="nounderline abstract_t">Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006; 2:130.</a></li><li><a class="nounderline abstract_t">Kreeger L, Duncan A, Cowap J. Psychostimulants used for opioid-induced drowsiness. J Pain Symptom Manage 1996; 11:1.</a></li><li><a class="nounderline abstract_t">Mercadante S, Serretta R, Casuccio A. Effects of caffeine as an adjuvant to morphine in advanced cancer patients. A randomized, double-blind, placebo-controlled, crossover study. J Pain Symptom Manage 2001; 21:369.</a></li><li><a class="nounderline abstract_t">Slatkin NE, Rhiner M, Bolton TM. Donepezil in the treatment of opioid-induced sedation: report of six cases. J Pain Symptom Manage 2001; 21:425.</a></li><li><a class="nounderline abstract_t">Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 2003; 26:1049.</a></li><li><a class="nounderline abstract_t">Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs 2013; 27:15.</a></li><li><a class="nounderline abstract_t">Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev 2014; :CD011056.</a></li><li><a class="nounderline abstract_t">Coluzzi F, Rocco A, Mandatori I, Mattia C. Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation. Curr Pharm Des 2012; 18:6043.</a></li><li><a class="nounderline abstract_t">Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19:2542.</a></li><li><a class="nounderline abstract_t">McDonald PP, Graham M, Clayton A, et al. Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med 1991; 5:323.</a></li><li><a class="nounderline abstract_t">De Conno F, Ripamonti C, Saita L, et al. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 1995; 13:1004.</a></li><li><a class="nounderline abstract_t">Babul N, Provencher L, Laberge F, et al. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 1998; 38:74.</a></li><li><a class="nounderline abstract_t">Bruera E, Fainsinger R, Spachynski K, et al. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 1995; 13:1520.</a></li><li><a class="nounderline abstract_t">Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med 2011; 25:442.</a></li><li><a class="nounderline abstract_t">Sande TA, Laird BJA, Fallon MT. The Management of Opioid-Induced Nausea and Vomiting in Patients with Cancer: A Systematic Review. J Palliat Med 2019; 22:90.</a></li><li><a class="nounderline abstract_t">Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clin Evid 2009; 2009.</a></li><li><a class="nounderline abstract_t">McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003; 4:231.</a></li><li><a class="nounderline abstract_t">Hardy J, Daly S, McQuade B, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer 2002; 10:231.</a></li><li><a class="nounderline abstract_t">Sussman G, Shurman J, Creed MR, et al. Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. Clin Ther 1999; 21:1216.</a></li><li><a class="nounderline abstract_t">Chung F, Lane R, Spraggs C, et al. Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. Eur J Anaesthesiol 1999; 16:669.</a></li><li><a class="nounderline abstract_t">Davis M, Hui D, Davies A, et al. MASCC antiemetics in advanced cancer updated guideline. Support Care Cancer 2021; 29:8097.</a></li><li><a class="nounderline abstract_t">Okamoto Y, Tsuneto S, Matsuda Y, et al. A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage 2007; 34:217.</a></li><li><a class="nounderline abstract_t">Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 2016; 375:134.</a></li><li><a class="nounderline abstract_t">Ferris FD, Kerr IG, Sone M, Marcuzzi M. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom Manage 1991; 6:389.</a></li><li><a class="nounderline abstract_t">Eisele JH Jr, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992; 49:231.</a></li><li><a class="nounderline abstract_t">Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010; 26:374.</a></li><li><a class="nounderline abstract_t">McWilliams K, Simmons C, Laird BJ, Fallon MT. A systematic review of opioid effects on the hypogonadal axis of cancer patients. Support Care Cancer 2014; 22:1699.</a></li><li><a class="nounderline abstract_t">de Vries F, Bruin M, Lobatto DJ, et al. Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">O'Rourke TK Jr, Wosnitzer MS. Opioid-Induced Androgen Deficiency (OPIAD): Diagnosis, Management, and Literature Review. Curr Urol Rep 2016; 17:76.</a></li><li><a class="nounderline abstract_t">AminiLari M, Manjoo P, Craigie S, et al. Hormone Replacement Therapy and Opioid Tapering for Opioid-Induced Hypogonadism Among Patients with Chronic Noncancer Pain: A Systematic Review. Pain Med 2019; 20:301.</a></li><li><a class="nounderline abstract_t">Jasuja GK, Ameli O, Reisman JI, et al. Health Outcomes Among Long-term Opioid Users With Testosterone Prescription in the Veterans Health Administration. JAMA Netw Open 2019; 2:e1917141.</a></li><li><a class="nounderline abstract_t">Rosen IM, Aurora RN, Kirsch DB, et al. Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement. J Clin Sleep Med 2019; 15:1671.</a></li><li class="breakAll">American Pain Society. Principles of Analgesic Use, 7th ed, American Pain Society, Chicago, IL 2016.</li><li class="breakAll">Fine P, Portenoy RK. Opioid analgesia. New York: McGraw Hill, 2004. http://www.stoppain.org/pcd/content/forpros/opioidbook.asp (Accessed on April 21, 2011).</li><li><a class="nounderline abstract_t">Quigley C. Opioids in people with cancer-related pain. BMJ Clin Evid 2008; 2008.</a></li><li><a class="nounderline abstract_t">Macleod J, Steer C, Tilling K, et al. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med 2019; 16:e1002965.</a></li><li><a class="nounderline abstract_t">Haider A, Azhar A, Nguyen K, et al. Concurrent use of opioids with benzodiazepines or nonbenzodiazepine sedatives among patients with cancer referred to an outpatient palliative care clinic. Cancer 2019; 125:4525.</a></li><li><a class="nounderline abstract_t">Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the Risk for Opioid-Related Death: A Nested Case-Control Study. Ann Intern Med 2018; 169:732.</a></li><li><a class="nounderline abstract_t">Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med 2017; 14:e1002396.</a></li><li class="breakAll">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin (Accessed on November 23, 2021).</li><li class="breakAll">FDA safety communication on discussing naloxone with all patients prescribed opioid pain relievers. US Food and Drug Administration. https://www.fda.gov/media/140360/download (Accessed on July 30, 2020).</li><li class="breakAll">American Academy of Hospice and Palliative Medicine www.aahpm.org/certification/index.html (Accessed on April 21, 2011).</li><li><a class="nounderline abstract_t">Ganesh A, Maxwell LG. Pathophysiology and management of opioid-induced pruritus. Drugs 2007; 67:2323.</a></li><li><a class="nounderline abstract_t">Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology 1985; 62:124.</a></li><li><a class="nounderline abstract_t">Warner MA, Hosking MP, Gray JR, et al. Narcotic-induced histamine release: a comparison of morphine, oxymorphone, and fentanyl infusions. J Cardiothorac Vasc Anesth 1991; 5:481.</a></li><li><a class="nounderline abstract_t">Ko MC, Song MS, Edwards T, et al. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 2004; 310:169.</a></li><li><a class="nounderline abstract_t">Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998; 16:121.</a></li><li><a class="nounderline abstract_t">Tarcatu D, Tamasdan C, Moryl N, Obbens E. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag 2007; 3:167.</a></li><li><a class="nounderline abstract_t">Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother 2001; 35:85.</a></li><li><a class="nounderline abstract_t">Yuan CS, Foss JF, O'Connor M, et al. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 1998; 52:161.</a></li><li><a class="nounderline abstract_t">Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf 2008; 31:373.</a></li><li><a class="nounderline abstract_t">Chen YP, Chen SR, Pan HL. Systemic morphine inhibits dorsal horn projection neurons through spinal cholinergic system independent of descending pathways. J Pharmacol Exp Ther 2005; 314:611.</a></li><li><a class="nounderline abstract_t">Meyboom RH, Brodie-Meijer CC, Diemont WL, van Puijenbroek EP. Bladder dysfunction during the use of tramadol. Pharmacoepidemiol Drug Saf 1999; 8 Suppl 1:S63.</a></li><li><a class="nounderline abstract_t">Wang J, Pennefather S, Russell G. Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia. Br J Anaesth 1998; 80:565.</a></li><li><a class="nounderline abstract_t">Rosow CE, Gomery P, Chen TY, et al. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther 2007; 82:48.</a></li><li><a class="nounderline abstract_t">Malinovsky JM, Lepage JY, Karam G, Pinaud M. Nalbuphine reverses urinary effects of epidural morphine: a case report. J Clin Anesth 2002; 14:535.</a></li><li><a class="nounderline abstract_t">Ibrahim AM, Obaidi Z, Ruan G, et al. Nalbuphine for Opioid-Induced Urine Retention. Ann Intern Med 2018; 169:894.</a></li><li><a class="nounderline abstract_t">Sacerdote P. Opioids and the immune system. Palliat Med 2006; 20 Suppl 1:s9.</a></li><li><a class="nounderline abstract_t">Shavit Y, Terman GW, Lewis JW, et al. Effects of footshock stress and morphine on natural killer lymphocytes in rats: studies of tolerance and cross-tolerance. Brain Res 1986; 372:382.</a></li><li><a class="nounderline abstract_t">Beilin B, Martin FC, Shavit Y, et al. Suppression of natural killer cell activity by high-dose narcotic anesthesia in rats. Brain Behav Immun 1989; 3:129.</a></li><li><a class="nounderline abstract_t">Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997; 121:834.</a></li><li><a class="nounderline abstract_t">Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc 2011; 59:1899.</a></li><li><a class="nounderline abstract_t">Wiese AD, Griffin MR, Stein CM, et al. Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study. Arthritis Rheumatol 2016; 68:323.</a></li><li><a class="nounderline abstract_t">Wiese AD, Griffin MR, Schaffner W, et al. Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study. Ann Intern Med 2018; 168:396.</a></li><li><a class="nounderline abstract_t">Wiese AD, Griffin MR, Schaffner W, et al. Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study. Clin Infect Dis 2019; 68:1862.</a></li><li><a class="nounderline abstract_t">Mysels DJ, Sullivan MA. The relationship between opioid and sugar intake: review of evidence and clinical applications. J Opioid Manag 2010; 6:445.</a></li><li><a class="nounderline abstract_t">Reece AS. An intriguing association between dental and mental pathology in addicted and control subjects: a cross-sectional survey. Br Dent J 2008; 205:E22.</a></li><li><a class="nounderline abstract_t">Titsas A, Ferguson MM. Impact of opioid use on dentistry. Aust Dent J 2002; 47:94.</a></li><li><a class="nounderline abstract_t">Morabia A, Fabre J, Chee E, et al. Diet and opiate addiction: a quantitative assessment of the diet of non-institutionalized opiate addicts. Br J Addict 1989; 84:173.</a></li><li><a class="nounderline abstract_t">Peles E, Schreiber S, Sason A, Adelson M. Risk factors for weight gain during methadone maintenance treatment. Subst Abus 2016; 37:613.</a></li><li><a class="nounderline abstract_t">Fenn JM, Laurent JS, Sigmon SC. Increases in body mass index following initiation of methadone treatment. J Subst Abuse Treat 2015; 51:59.</a></li><li><a class="nounderline abstract_t">Bogucka-Bonikowska A, Baran-Furga H, Chmielewska K, et al. Taste function in methadone-maintained opioid-dependent men. Drug Alcohol Depend 2002; 68:113.</a></li><li><a class="nounderline abstract_t">Nolan LJ, Scagnelli LM. Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Subst Use Misuse 2007; 42:1555.</a></li><li><a class="nounderline abstract_t">Zador D, Lyons Wall PM, Webster I. High sugar intake in a group of women on methadone maintenance in south western Sydney, Australia. Addiction 1996; 91:1053.</a></li><li><a class="nounderline abstract_t">Flory JH, Wiesenthal AC, Thaler HT, et al. Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain. J Pain Symptom Manage 2016; 51:79.</a></li><li><a class="nounderline abstract_t">Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis 2006; 24:105.</a></li><li><a class="nounderline abstract_t">Giugliano D. Morphine, opioid peptides, and pancreatic islet function. Diabetes Care 1984; 7:92.</a></li><li><a class="nounderline abstract_t">Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002; 22:8312.</a></li><li><a class="nounderline abstract_t">Vanderah TW, Suenaga NM, Ossipov MH, et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 2001; 21:279.</a></li><li><a class="nounderline abstract_t">Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep 2006; 10:67.</a></li><li><a class="nounderline abstract_t">Roeckel LA, Le Coz GM, Gavériaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: Cellular and molecular mechanisms. Neuroscience 2016; 338:160.</a></li><li><a class="nounderline abstract_t">Bannister K, Dickenson AH. Opioid hyperalgesia. Curr Opin Support Palliat Care 2010; 4:1.</a></li><li><a class="nounderline abstract_t">Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep 2011; 15:129.</a></li><li><a class="nounderline abstract_t">Fishbain DA, Cole B, Lewis JE, et al. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009; 10:829.</a></li><li><a class="nounderline abstract_t">Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008; 24:479.</a></li><li><a class="nounderline abstract_t">Eisenberg E, Suzan E, Pud D. Opioid-induced hyperalgesia (OIH): a real clinical problem or just an experimental phenomenon? J Pain Symptom Manage 2015; 49:632.</a></li><li><a class="nounderline abstract_t">Higgins C, Smith BH, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth 2019; 122:e114.</a></li><li><a class="nounderline abstract_t">Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations. CNS Drugs 2015; 29:465.</a></li><li><a class="nounderline abstract_t">Induru RR, Davis MP. Buprenorphine for neuropathic pain--targeting hyperalgesia. Am J Hosp Palliat Care 2009; 26:470.</a></li></ol></div><div id="topicVersionRevision">Topic 2800 Version 78.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17916540" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The narcotic bowel syndrome: clinical features, pathophysiology, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26557892" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evolving paradigms in the treatment of opioid-induced bowel dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19670020" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19662923" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977159" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185430" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14594516" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9212478" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19824278" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18363493" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21937568" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144627" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bowel Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12870773" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of straining during defecation in three positions: results and implications for human health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30898031" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A review on squat-assist devices to aid elderly with lower limb difficulties in toileting to tackle constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9436336" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of senna versus lactulose in terminal cancer patients treated with opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31321524" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : PEG vs. sennosides for opioid-induced constipation in cancer care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9505981" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880080" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16875112" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25967924" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Laxatives for the management of constipation in people receiving palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205879" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21249653" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Laxatives or methylnaltrexone for the management of constipation in palliative care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232639" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fructooligosaccharides and lactulose cause more symptoms in lactose maldigesters and subjects with pseudohypolactasia than in control lactose digesters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23261065" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : American Gastroenterological Association technical review on constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22889861" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32488259" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30340754" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19912069" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36106667" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23752879" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28919541" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Drugs for Treating Opioid-Induced Constipation: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29374616" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29329690" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Author's Response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19831162" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term use of methylnaltrexone for the management of constipation in advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28810695" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18509120" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Methylnaltrexone for opioid-induced constipation in advanced illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27860208" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28162731" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : (480) Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10989399" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Oral methylnaltrexone for opioid-induced constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24176612" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A prospective study of methylnaltrexone for opioid-induced constipation in advanced illness: should we use it or not?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045373" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21386935" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Utilization of methylnaltrexone (relistor) for opioid-induced constipation in an oncology hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21386935" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Utilization of methylnaltrexone (relistor) for opioid-induced constipation in an oncology hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24896818" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Naloxegol for opioid-induced constipation in patients with noncancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23726675" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34120247" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34120247" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28576452" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28371937" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29419653" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29419653" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968171" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968171" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1623695" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of opioid-induced constipation with oral naloxone: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800821" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292169" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772912" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772912" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19032132" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19243306" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779668" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Low-dose oral naloxone reverses opioid-induced constipation and analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18762438" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541841" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Low absolute bioavailability of oral naloxone in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26110375" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736104" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24716835" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25916220" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29016868" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29118557" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effects of probiotic-containing products on stool frequency and intestinal transit in constipated adults: systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25099542" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28034973" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31396746" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : MASCC recommendations on the management of constipation in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30016389" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28397700" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Narcotic bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19367263" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100280" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25349684" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prevalence of narcotic bowel syndrome in opioid abusers in iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144628" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Centrally Mediated Disorders of Gastrointestinal Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25207609" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The narcotic bowel syndrome: a recent update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357785" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755795" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pharmacologic treatment of opioid-induced sedation in chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773187" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Palliative uses of methylphenidate in patients with cancer: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539701" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1589233" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3791269" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Methylphenidate associated with narcotics for the treatment of cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20870687" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : European Palliative Care Research collaborative pain guidelines. Central side-effects management: what is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2703735" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11712723" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Modafinil: a gift to portmanteau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873263" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Modafinil treatment of opioid-induced sedation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17319446" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Modafinil: is it ready for prime time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8815145" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Psychostimulants used for opioid-induced drowsiness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369156" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effects of caffeine as an adjuvant to morphine in advanced cancer patients. A randomized, double-blind, placebo-controlled, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369163" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Donepezil in the treatment of opioid-induced sedation: report of six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14585555" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23160939" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24874470" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22747538" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11331334" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Strategies to manage the adverse effects of oral morphine: an evidence-based report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7707099" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9597563" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751901" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21708851" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30239277" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The Management of Opioid-Induced Nausea and Vomiting in Patients with Cancer: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19445763" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Nausea and vomiting in people with cancer and other chronic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14622694" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904788" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10463519" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583349" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34398289" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : MASCC antiemetics in advanced cancer updated guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17544249" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27410922" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1880439" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Transdermal scopolamine use in the control of narcotic-induced nausea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1376887" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20473043" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633592" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : A systematic review of opioid effects on the hypogonadal axis of cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31511863" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27586511" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Opioid-Induced Androgen Deficiency (OPIAD): Diagnosis, Management, and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29727002" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Hormone Replacement Therapy and Opioid Tapering for Opioid-Induced Hypogonadism Among Patients with Chronic Noncancer Pain: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31825502" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Health Outcomes Among Long-term Opioid Users With Testosterone Prescription in the Veterans Health Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31739858" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31739858" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31739858" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19445735" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Opioids in people with cancer-related pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31770388" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31460669" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Concurrent use of opioids with benzodiazepines or nonbenzodiazepine sedatives among patients with cancer referred to an outpatient palliative care clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30140853" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Pregabalin and the Risk for Opioid-Related Death: A Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972983" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972983" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972983" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972983" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17983254" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Pathophysiology and management of opioid-induced pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2578752" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718477" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Narcotic-induced histamine release: a comparison of morphine, oxymorphone, and fentanyl infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15044556" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : The role of central mu opioid receptors in opioid-induced itch in primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737103" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Paroxetine for pruritus in advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18027543" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11197589" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Opioid antagonists in the treatment of opioid-induced constipation and pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9800145" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422378" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Drug-induced urinary retention: incidence, management and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15845859" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Systemic morphine inhibits dorsal horn projection neurons through spinal cholinergic system independent of descending pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073888" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Bladder dysfunction during the use of tramadol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9640172" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392726" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12477591" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Nalbuphine reverses urinary effects of epidural morphine: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30178006" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Nalbuphine for Opioid-Induced Urine Retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16764216" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Opioids and the immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3011211" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Effects of footshock stress and morphine on natural killer lymphocytes in rats: studies of tolerance and cross-tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2477090" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Suppression of natural killer cell activity by high-dose narcotic anesthesia in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9208156" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22091503" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26473742" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29435555" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30239630" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21269006" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : The relationship between opioid and sugar intake: review of evidence and clinical applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18953330" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : An intriguing association between dental and mental pathology in addicted and control subjects: a cross-sectional survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12139280" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Impact of opioid use on dentistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2720181" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Diet and opiate addiction: a quantitative assessment of the diet of non-institutionalized opiate addicts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27093441" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Risk factors for weight gain during methadone maintenance treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25441923" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Increases in body mass index following initiation of methadone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12167557" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Taste function in methadone-maintained opioid-dependent men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17918026" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8688819" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : High sugar intake in a group of women on methadone maintenance in south western Sydney, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342726" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16699269" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Opioid-induced gastrointestinal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368156" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Morphine, opioid peptides, and pancreatic islet function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12223586" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11150345" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16499832" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Opioid-induced abnormal pain sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27346146" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Opioid-induced hyperalgesia: Cellular and molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019618" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Opioid hyperalgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21225380" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19594845" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Do opioids induce hyperalgesia in humans? An evidence-based structured review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574358" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25128284" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Opioid-induced hyperalgesia (OIH): a real clinical problem or just an experimental phenomenon?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30915985" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26142224" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19666890" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Buprenorphine for neuropathic pain--targeting hyperalgesia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
